0001285819-16-000017.txt : 20160510 0001285819-16-000017.hdr.sgml : 20160510 20160510072110 ACCESSION NUMBER: 0001285819-16-000017 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 50 CONFORMED PERIOD OF REPORT: 20160331 FILED AS OF DATE: 20160510 DATE AS OF CHANGE: 20160510 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OMEROS CORP CENTRAL INDEX KEY: 0001285819 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 911663741 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-34475 FILM NUMBER: 161633671 BUSINESS ADDRESS: STREET 1: 201 ELLIOTT AVENUE WEST CITY: SEATTLE STATE: WA ZIP: 98119 BUSINESS PHONE: 206-676-5000 MAIL ADDRESS: STREET 1: 201 ELLIOTT AVENUE WEST CITY: SEATTLE STATE: WA ZIP: 98119 10-Q 1 omer-20160331x10q.htm 10-Q SEC Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 ________________________________________
FORM 10-Q
 ________________________________________
(Mark One)
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2016
or
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     
Commission file number: 001-34475
 ________________________________________
OMEROS CORPORATION
(Exact name of registrant as specified in its charter)
 ________________________________________
Washington
 
91-1663741
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification Number)
 
 
 
201 Elliott Avenue West
Seattle, Washington
 
98119
(Address of principal executive offices)
 
(Zip Code)
(206) 676-5000
(Registrant’s telephone number, including area code)
 ________________________________________
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer
 
¨
  
Accelerated filer
 
x
Non-accelerated filer
 
¨ (Do not check if a smaller reporting company)
  
Smaller reporting company
 
¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x
As of May 2, 2016, the number of outstanding shares of the registrant’s common stock, par value $0.01 per share, was 39,135,054.




SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act, which are subject to the “safe harbor” created by those sections for such statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. All statements other than statements of historical fact are “forward-looking statements.” Terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions and variations thereof are intended to identify forward-looking statements, but these terms are not the exclusive means of identifying such statements. Examples of these statements include, but are not limited to, statements regarding:
our plans for sales, marketing and distribution of OMIDRIA® (phenylephrine and ketorolac injection) 1%/0.3%;
our expectations regarding our product sales and our estimate regarding how long our existing cash, cash equivalents, short-term investments and revenues will be sufficient to fund our anticipated operating expenses, capital expenditures and interest and principal payments on our outstanding notes under our Loan and Security Agreement, or the Oxford/EWB Loan Agreement, with Oxford Finance LLC, or Oxford, and East West Bank, or EWB;
our ability to raise additional capital through the capital markets, including under our at-the-market equity facility with JonesTrading Institutional Services LLC, or JonesTrading, or through one or more corporate partnerships, equity offerings, debt financings, collaborations, licensing arrangements or asset sales;
our ability to forecast accurately wholesaler demand as well as our estimates of chargebacks and rebates, distribution fees and estimated product returns;
our ability to enter into acceptable arrangements with potential corporate partners, including with respect to OMIDRIA;
our expectations regarding the clinical, therapeutic and competitive benefits of OMIDRIA and our product candidates;
our anticipation that we will rely on contract manufacturers to manufacture OMIDRIA for commercial sale and to manufacture our product candidates and our expectations regarding product supply and manufacturing of OMIDRIA;
our expectations about the commercial competition that OMIDRIA and our product candidates, if commercialized, may face;
our expectation that the OMIDRIAssure™ Reimbursement Services Program will increase patient access to OMIDRIA;
the extent of protection that our patents provide and that our pending patent applications will provide, if patents issue from such applications, for our technologies, programs, products and product candidates;
when or whether the dosing limitations in our OMS824 program may be removed;
our ability to design and successfully complete clinical trials and other studies for our products and product candidates and our plans and expectations regarding our clinical trials, including our clinical trials for OMS721 and for OMS824;
the expected course and costs of existing claims, legal proceedings and administrative actions, our involvement in potential claims, legal proceedings and administrative actions, and the potential outcomes and effects of both existing and potential claims, legal proceedings and administrative actions, as well as regulatory determinations, on our business, prospects, financial condition and results of operations;
our expectations regarding our OMS103 exclusive license agreement including, without limitation, the manufacturing and commercialization of OMS103 and the commencement and subsequent continuation of product sales on which we could receive royalty revenue; and
our expected financial position, performance, revenues, growth, expenses, magnitude of net losses and the availability of resources.
Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including the risks, uncertainties and other factors described in Item IA of Part II of this Quarterly Report on Form 10-Q under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and in our other filings with the Securities and Exchange Commission, or SEC. Given these risks, uncertainties and other factors, actual results or anticipated developments may not be realized or, even if substantially realized, may not have the expected consequences to or effects on our company, business or operations. Accordingly, you should not place undue reliance on these forward-looking statements, which represent our estimates and assumptions only as of the date of the filing of this Quarterly Report on Form 10-Q. You should read this Quarterly Report on Form 10-Q completely and with the understanding that our actual results in subsequent periods may materially differ from current expectations. Except as required by applicable



law, including the securities laws of the United States and the rules and regulations of the SEC, we assume no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events or otherwise.



OMEROS CORPORATION
FORM 10-Q FOR THE QUARTER ENDED March 31, 2016
INDEX
 



PART I—FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
OMEROS CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)
(unaudited)
 
 
March 31,
2016
 
December 31,
2015
Assets
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
978

 
$
1,365

Short-term investments
12,266

 
26,898

Receivables
6,646

 
6,517

Inventory
1,972

 
472

Prepaid expense
2,460

 
1,894

Total current assets
24,322

 
37,146

Property and equipment, net
898

 
951

Restricted cash and investments
10,679

 
10,679

Other assets
73

 
219

Total assets
$
35,972

 
$
48,995

 
 
 
 
Liabilities and shareholders’ deficit
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
5,332

 
$
6,428

Accrued expenses
12,120

 
9,752

Current portion of notes payable
69

 
73

Total current liabilities
17,521

 
16,253

Notes payable, net
49,973

 
49,769

Deferred rent
9,220

 
9,207

Commitments and contingencies (Note 8)

 

Shareholders’ deficit:
 
 
 
Preferred stock, par value $0.01 per share, 20,000,000 authorized and none issued and outstanding at March 31, 2016 and December 31, 2015

 

Common stock, par value $0.01 per share, 150,000,000 authorized at March 31, 2016 and December 31, 2015; 39,119,154 and 38,040,891 issued and outstanding at March 31, 2016 and December 31, 2015, respectively
391

 
380

Additional paid-in capital
382,548

 
376,528

Accumulated deficit
(423,681
)
 
(403,142
)
Total shareholders’ deficit
(40,742
)
 
(26,234
)
Total liabilities and shareholders’ deficit
$
35,972

 
$
48,995

See notes to condensed consolidated financial statements

-3-


OMEROS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except share and per share data)
(unaudited)
 
 
Three Months Ended  
 March 31,
 
2016
 
2015
Revenues
 
 
 
Product sales, net
$
7,246

 
$
238

Grant revenue
173

 
150

Total revenue
7,419

 
388

 
 
 
 
Costs and expenses
 
 
 
Cost of product sales
327

 
11

Research and development
15,434

 
9,318

Selling, general and administrative
11,110

 
8,989

Total costs and expenses
26,871

 
18,318

Loss from operations
(19,452
)
 
(17,930
)
Interest expense
(1,375
)
 
(957
)
Other income (expense), net
288

 
218

Net loss
$
(20,539
)
 
$
(18,669
)
Comprehensive loss
$
(20,539
)
 
$
(18,669
)
Basic and diluted net loss per share
$
(0.54
)
 
$
(0.51
)
Weighted-average shares used to compute basic and diluted net loss per share
38,317,084

 
36,483,559

See notes to condensed consolidated financial statements

-4-


OMEROS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(unaudited)
 
 
Three Months Ended 
 March 31,
 
2016

2015
Operating activities:
 
 
 
Net loss
$
(20,539
)
 
$
(18,669
)
Adjustments to reconcile net loss to net cash used in operating activities:
 
 
 
Depreciation and amortization
53

 
55

Stock-based compensation expense
4,422

 
2,517

Non-cash interest expense
213

 
212

Changes in operating assets and liabilities:
 
 
 
Receivables
(129
)
 
(146
)
Inventory
(1,500
)
 

Prepaid expenses and other noncurrent assets
(420
)
 
725

Accounts payable and accrued expenses
1,272

 
(2,170
)
Net cash used in operating activities
(16,628
)
 
(17,476
)
Investing activities:
 
 
 
Purchases of investments
(18
)
 
(79,389
)
Proceeds from the sale and maturities of investments
14,650

 
17,300

Net cash provided by (used in) investing activities
14,632

 
(62,089
)
Financing activities:
 
 
 
Proceeds from issuance of common stock and pre-funded warrants, net

 
79,076

Proceeds upon exercise of stock options and warrants
1,609

 
1,576

Net cash provided by financing activities
1,609

 
80,652

Net (decrease) increase in cash and cash equivalents
(387
)
 
1,087

Cash and cash equivalents at beginning of period
1,365

 
354

Cash and cash equivalents at end of period
$
978

 
$
1,441

Supplemental cash flow information
 
 
 
Cash paid for interest
$
776

 
$
745

See notes to condensed consolidated financial statements

-5-


OMEROS CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
Note 1—Organization and Significant Accounting Policies
Organization
We are a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Our first drug product OMIDRIA was approved by the United States (U.S.) Food and Drug Administration (FDA) for use during cataract surgery or intraocular lens replacement. We broadly launched OMIDRIA in the U.S. in April 2015.
Basis of Presentation
Our condensed consolidated financial statements include the financial position and results of operations of Omeros Corporation (Omeros) and our wholly owned subsidiaries. All inter-company transactions have been eliminated and we have determined we operate in one segment. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. The information as of March 31, 2016 and for the three months ended March 31, 2016 and 2015 includes all adjustments, which include normal recurring adjustments, necessary to present fairly our interim financial information. The Condensed Consolidated Balance Sheet at December 31, 2015 has been derived from our audited financial statements but does not include all of the information and footnotes required by GAAP.
The accompanying unaudited condensed consolidated financial statements and related notes thereto should be read in conjunction with the audited consolidated financial statements and related notes thereto that are included within our Annual Report on Form 10-K for the year ended December 31, 2015, which was filed with the U.S. Securities and Exchange Commission (SEC) on March 15, 2016.
Product Sales, Net
We record revenue from OMIDRIA product sales when the product is delivered to our wholesalers.
Product sales are recorded net of estimated chargebacks and rebates, wholesaler distribution fees and estimated product returns. Accruals or allowances are established for these deductions when revenue is recognized, and actual amounts incurred are offset against the applicable accruals and allowances. We reflect each of these accruals or allowances as either a reduction in the related accounts receivable or as an accrued liability, depending on how the accrual or allowance is settled.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant items subject to such estimates include revenue recognition, fair market value of investments, stock-based compensation expense and accruals for clinical trials and contingencies. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances; however, actual results could differ from these estimates.

-6-


Liquidity and Capital Resources
As of March 31, 2016, we had $13.2 million in cash, cash equivalents and short-term investments. In addition, we have $10.0 million in restricted cash and investments that must be maintained in depository and investment accounts pursuant to the Loan and Security Agreement (the Oxford/EWB Loan Agreement) entered into in December 2015 with Oxford Finance LLC (Oxford) and East West Bank (EWB) as well as $679,000 used to secure a letter of credit for the Omeros Building lease. We expect to continue to incur losses until such time as OMIDRIA product sales, corporate partnerships and/or licensing revenues from products or programs are adequate to support our ongoing operating expenses and debt service. We are unable to predict if or when this may occur, and until it does occur, we will need to continue to raise additional funds through public or private equity securities sales, including under our At Market Issuance Sales Agreement (the ATM Agreement) with JonesTrading Institutional Services LLC (JonesTrading) (see Note 9 for further detail), through the incurrence of additional debt, through corporate partnerships, through asset sales or through the pursuit of collaborations and licensing arrangements related to certain of our products or programs. These conditions raise a substantial doubt about our ability to continue as a going concern. If we are unable to become cash-flow positive or to raise additional capital as and when needed, or upon acceptable terms, such failure would have a significant negative impact on our financial condition.
The accompanying unaudited condensed consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.  The accompanying unaudited condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to our ability to continue as a going concern.
Recently Adopted Accounting Pronouncements
For the year ended December 31, 2015 we adopted and applied retrospectively Financial Accounting Standards Board (FASB) Accounting Standards Update, or ASU, No. 2015-03, related to simplifying the presentation of debt issuance costs. This standard requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction to the liability. The adoption of ASU 2015-03 resulted in the reclassification of $226,000 of debt issuance costs in our March 31, 2015 Condensed Consolidated Statement of Cash Flows.
Recent Accounting Pronouncements
In February 2016, FASB issued ASU 2016-02 related to lease accounting. This standard requires lessees to recognize a right-of-use asset and a lease liability for most leases. This standard must be applied using a modified retrospective transition and is effective for all annual and interim periods beginning after December 15, 2018. Earlier adoption is permitted. We are evaluating how this new standard will impact the presentation of our financial statements and related disclosures.
In March 2016, FASB issued ASU 2016-08 related to revenue recognition. This standard is an amendment to ASU 2014-09 relating to revenue from contracts with customers. This amendment clarifies an entity’s revenue recognition for a performance obligation based on principal versus agent considerations. This standard must be applied retroactively to each prior reporting period presented or retrospectively with the cumulative effect of applying the standard recognized in the period adopted. As amended, the standard is effective for interim and annual periods beginning after December 15, 2017 and cannot be adopted before that effective date. We are currently evaluating the impact that this standard may have on our financial statements once it is adopted.
In March 2016, the FASB issued ASU 2016-09 that changes the accounting for certain aspects of share-based payments to employees. The guidance requires the recognition of the income tax effects of awards in the income statement when the awards vest or are settled, thus eliminating additional paid in capital pools. The guidance also allows for the employer to repurchase more of an employee’s shares for tax withholding purposes without triggering liability accounting and for making a policy election to account for forfeitures as they occur rather than on an estimated basis. The guidance is effective for interim and annual periods beginning after December 15, 2016 with early adoption permitted. We are currently evaluating the impact that this standard may have on our financial statements once it is adopted and the timing of adoption.

Note 2—Net Loss Per Share
Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common share equivalents outstanding for the period, determined using the treasury-stock method.
The basic and diluted net loss per share amounts for the three months ended March 31, 2016 and 2015 were computed based on the shares of common stock outstanding during the respective periods. Potentially dilutive securities excluded from the diluted loss per share calculation are as follows:

-7-


 
March 31,
 
2016
 
2015
Outstanding options to purchase common stock
9,302,348

 
8,365,741

Warrants and pre-funded warrants to purchase common stock

 
1,160,788

Total
9,302,348

 
9,526,529



Note 3—Cash, Cash Equivalents and Investments
As of March 31, 2016 and December 31, 2015, all investments are classified as short-term and available-for-sale on the accompanying Condensed Consolidated Balance Sheets. We did not own any securities with unrealized loss positions as of March 31, 2016 or December 31, 2015. Investment income, which is included as a component of other income (expense), consists of interest earned.

Note 4—Fair-Value Measurements
On a recurring basis, we measure certain financial assets at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The accounting standard establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required:
Level 1—Observable inputs for identical assets or liabilities, such as quoted prices in active markets;
Level 2—Inputs other than quoted prices in active markets that are either directly or indirectly observable; and
Level 3—Unobservable inputs in which little or no market data exists, therefore they are developed using estimates and assumptions developed by us, which reflect those that a market participant would use.
Our fair value hierarchy for our financial assets and liabilities measured at fair value on a recurring basis are as follows:
 
March 31, 2016
 
Level 1
 
Level 2
 
Level 3
 
Total
 
(In thousands)
Assets:
 
 
 
 
 
 
 
Money-market funds classified as non-current restricted cash and investments
$
10,679

 
$

 
$

 
$
10,679

Money-market funds classified as short-term investments
12,266

 

 

 
12,266

Total
$
22,945

 
$

 
$

 
$
22,945

 
 
December 31, 2015
 
Level 1
 
Level 2
 
Level 3
 
Total
 
(In thousands)
Assets:
 
 
 
 
 
 
 
Money-market funds classified as non-current restricted cash and investments
$
10,679

 
$

 
$

 
$
10,679

Money-market funds classified as short-term investments
26,898

 

 

 
26,898

Total
$
37,577

 
$

 
$

 
$
37,577

Cash held in demand deposit accounts of $978,000 and $1.4 million is excluded from our fair-value hierarchy disclosure as of March 31, 2016 and December 31, 2015, respectively. There were no unrealized gains and losses associated with our short-term investments as of March 31, 2016 or December 31, 2015. The carrying amounts reported in the accompanying Condensed Consolidated Balance Sheets for receivables, accounts payable and other current monetary assets and liabilities approximate fair value because of the immediate or short-term maturity of these financial instruments.


-8-


Note 5—Inventory

The components of inventory are as follows:

 
March 31, 2016
 
December 31, 2015
 
(In thousands)
Raw materials
$
104

 
$
93

Work-in-process
1,692

 
158

Finished goods
176

 
221

Total inventory
$
1,972

 
$
472


Work-in-process consists of manufactured vials of OMIDRIA which have not been packaged into finished goods.


Note 6—Accrued Liabilities
Accrued liabilities consisted of the following:
 
March 31,
2016
 
December 31,
2015
 
(In thousands)
Contract research and development
$
3,260

 
$
2,973

Consulting and professional fees
3,232

 
2,400

Employee compensation
2,544

 
2,590

Clinical trials
2,061

 
1,108

Other accruals
1,023

 
681

       Total accrued liabilities
$
12,120

 
$
9,752


Note 7—Notes Payable
In December 2015, we entered into the Oxford/EWB Loan Agreement pursuant to which we borrowed $50.0 million. We can also borrow an additional $20.0 million in two tranches of $10.0 million each through June 30, 2017, contingent upon the satisfaction of certain conditions including minimum net revenues from OMIDRIA. The Oxford/EWB Loan Agreement requires interest-only payments through July 1, 2017. Beginning in August 2017, principal and interest payments are due through the January 1, 2020 maturity date.
The Oxford/EWB Loan Agreement contains covenants that require us to maintain $10.0 million in restricted cash and certain eligible term investments and limit or restrict our ability to enter into certain transactions. In addition, we are required to either meet an annual OMIDRIA net revenue minimum for 2016 of $70.0 million and quarterly OMIDRIA revenue minimums in 2017 and 2018, or maintain 50% of the then-outstanding note payable balance in restricted cash and certain eligible term investments. The Oxford/EWB Loan Agreement also includes provisions related to events of default, the occurrence of a material adverse effect (MAE) and changes of control. The occurrence of an event of default could result in the acceleration of the Oxford/EWB Loan Agreement and, under certain circumstances, could increase our interest rate by 5.0% per annum during the period of default. There was no event of default under the Oxford/EWB Loan Agreement as of March 31, 2016.
As of March 31, 2016, the remaining unamortized discount and debt issuance costs associated with the debt were $3.6 million and $414,000, respectively.


-9-


Note 8—Commitments and Contingencies
Development Milestones and Product Royalties
We have retained control of worldwide commercial rights to OMIDRIA, to all of our product candidates and to our programs other than OMS103. We may be required, in connection with existing in-licensing or asset acquisition agreements, to make certain royalty and milestone payments and we cannot, at this time, determine when or if the related milestones will be achieved or whether the events triggering the commencement of payment obligations will occur. See Note 9 to our Consolidated Financial Statements for the year ended December 31, 2015 included within our Annual Report on Form 10-K as filed with the SEC on March 15, 2016.
Litigation
As described within Note 9 of the “Notes to Consolidated Financial Statements” included within our Annual Report on Form 10-K for the year ended December 31, 2015 filed with the SEC on March 15, 2016, we filed a patent infringement lawsuit against Par Pharmaceutical, Inc. and its subsidiary, Par Sterile Products, LLC (collectively, Par) following our receipt of a Paragraph IV Notice Letter from Par stating Par is seeking approval from the FDA to market a generic version of OMIDRIA. During 2016, we amended the lawsuit asserting an additional OMIDRIA patent, which was granted by the U.S. Patent and Trademark Office after Par filed its original Paragraph IV Notice Letter. We have filed suit against Par, thereby triggering a stay which is expected to remain in effect until January 2018 of the FDA’s final approval of Par’s ANDA. We continue to believe that the assertions in Par’s Paragraph IV Notice Letter do not have merit and we intend to prosecute vigorously our patent infringement claims against Par.

Note 9—Shareholders’ Equity
Common Stock
At Market Issuance Sales Agreement - In January 2016, we entered into the ATM Agreement with JonesTrading pursuant to which we may direct JonesTrading to sell shares of our common stock with an aggregate offering price of up to $100.0 million directly on The Nasdaq Global Market, through a market maker other than on an exchange or in negotiated transactions. Any sales made under the ATM Agreement are based solely on our instructions and JonesTrading will receive a 1.7% commission from the gross proceeds. The ATM Agreement may be terminated by either party at any time upon 10 days' notice to the other party or by JonesTrading at any time in certain circumstances including the occurrence of a material adverse effect to Omeros.
Securities Offering - In February 2015, we sold 3.4 million shares of our common stock at a public offering price of $20.03 per share and sold pre-funded warrants to purchase up to 749,250 shares of our common stock at a public offering price of $20.02 per pre-funded warrant share. The public offering price for the pre-funded warrants was equal to the public offering price of our common stock, less the $0.01 per share exercise price of each pre-funded warrant. After deducting underwriter discounts and offering expenses of $4.9 million, we received net proceeds from the offering of $79.1 million.
Warrants
For the three months ended March 31, 2016, we received cash proceeds of approximately $7,500 upon the cash exercise of our then-outstanding pre-funded warrants, which had a weighted average exercise price of $0.01 per share, that resulted in the issuance of 749,250 shares of our common stock.
For the three months ended March 31, 2015, we received proceeds of $1.4 million upon the exercise of warrants to purchase approximately 126,000 shares of our common stock.



-10-


Note 10—Stock-Based Compensation
Stock-based compensation expense includes amortization of stock options granted to employees and non-employees and has been reported in our Condensed Consolidated Statements of Operations and Comprehensive Loss as follows:
 
 
Three Months Ended  
 March 31,
 
2016
 
2015
 
(In thousands)
Research and development
$
2,155

 
$
1,324

Selling, general and administrative
2,267

 
1,193

Total
$
4,422

 
$
2,517


In February 2016, in connection with our annual employee review process, we granted qualified employees options to purchase approximately 1.3 million shares of our common stock with an exercise price of $10.27.
The fair value of each option grant to employees and directors is estimated on the date of grant using the Black-Scholes option-pricing model. The following assumptions were applied to employee and director stock option grants during the periods ended:
 
Three Months Ended  
 March 31,
 
2016
 
2015
Estimated weighted-average fair value
$
6.62

 
$
13.49

Weighted-average assumptions
 
 
 
Expected volatility
74
%
 
70
%
Expected term, in years
5.7

 
6.0

Risk-free interest rate
1.44
%
 
1.51
%
Expected dividend yield
%
 
%

Stock option activity for all stock plans and related information is as follows:
 
 
Options
Outstanding
 
Weighted-
Average
Exercise
Price per
Share
 
Remaining
Contractual Life
(In years)
 
Aggregate
Intrinsic
Value
(In thousands)
Balance at December 31, 2015
8,310,235

 
$
7.97

 
 
 
 
   Granted
1,349,055

 
10.31

 
 
 
 
   Exercised
(329,013
)
 
4.87

 
 
 
 
   Forfeited
(27,929
)
 
14.51

 
 
 
 
Balance at March 31, 2016
9,302,348

 
$
8.40

 
6.54
 
$
65,720

Vested and expected to vest at March 31, 2016
9,012,412

 
$
8.30

 
6.46
 
$
64,505

Exercisable at March 31, 2016
6,486,712

 
$
7.09

 
5.50
 
$
53,722

At March 31, 2016, excluding non-employee stock options, the total estimated compensation expense to be recognized in connection with our unvested options is $16.6 million and 2,189,575 shares were available to grant.

-11-


ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis should be read in conjunction with the unaudited consolidated financial statements and notes thereto included elsewhere in this Quarterly Report on Form 10-Q.
Overview
We are a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system.
Our marketed drug product OMIDRIA® (phenylephrine and ketorolac injection) 1%/0.3% was broadly launched in the U.S. in April 2015 for use during cataract surgery or intraocular lens, or IOL, replacement. OMIDRIA is derived from our proprietary PharmacoSurgery® platform, which is designed to improve clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological and other surgical procedures. Our proprietary PharmacoSurgery platform is based on low-dose combinations of U.S. Food and Drug Administration-approved, or FDA-approved, therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma and to provide clinical benefits both during and after surgery.
In our pipeline we have clinical-stage development programs focused on: complement-related thrombotic microangiopathies; complement-mediated glomerulopathies; Huntington’s disease and cognitive impairment; addictive and compulsive disorders; and problems associated with urologic surgical procedures. In addition, we have a diverse group of preclinical programs and two additional platforms: one capable of unlocking new G protein-coupled receptor, or GPCR, drug targets and the other used to generate antibodies. For OMIDRIA and each of our product candidates and our programs, other than OMS103, we have retained control of all commercial rights.
Products, Product Candidates, Development Programs and Platforms
OMIDRIA. OMIDRIA is approved in the U.S. by the FDA for use during cataract surgery or IOL replacement to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain, and is approved in all European Union, or EU, member states plus Iceland, Lichtenstein and Norway for use during cataract surgery and other IOL replacement procedures to maintain mydriasis (pupil dilation), to prevent miosis (pupil constriction), and to reduce postoperative eye pain. We broadly launched OMIDRIA in the U.S. in April 2015 primarily through wholesalers which, in turn, sell to ambulatory surgery centers, or ASCs, and hospitals. The Centers for Medicare and Medicaid Services, or CMS, has granted transitional pass-through reimbursement status for OMIDRIA, which we expect to run until January 1, 2018. Pass-through status allows for separate payment (i.e., outside the bundled payment) under Medicare Part B for new drugs and other medical technologies that meet well-established criteria specified by federal regulations governing Medicare spending. In January 2016, we announced the results of certain investigator-initiated studies of OMIDRIA that demonstrate statistically significant reduction in small pupil-associated complication rates, in usage of costly pupil-expanding devices and in age-adjusted surgical times together with statistically significant improvement in uncorrected visual acuity on the day after surgery and in prevention of miosis during femtosecond laser-assisted surgery; these outcomes are not referenced in the currently approved labeling for OMIDRIA.
In May 2016, we entered into an exclusive supply and distribution agreement with ITROM Trading Drug Store, or ITROM, for the sale of OMIDRIA in the Kingdom of Saudi Arabia, the United Arab Emirates and certain other countries in the Middle East. Within the licensed territory, ITROM is responsible for obtaining marketing authorizations for OMIDRIA, on our behalf, and for promoting, marketing, selling and distributing product supplied by us. We expect ITROM will begin selling OMIDRIA later this year.
OMS103. OMS103, derived from our PharmacoSurgery platform, was developed for use during all arthroscopic procedures, including knee and shoulder arthroscopy, and completed Phase 3 trials in patients undergoing arthroscopic anterior cruciate ligament reconstruction and arthroscopic partial meniscectomy. In June 2015, we entered into an exclusive licensing agreement, or the OMS103 Agreement, with Fagron Compounding Services, LLC, d/b/a Fagron Sterile Services, and JCB Laboratories, LLC, or collectively Fagron, an FDA-registered human drug outsourcing facility, under which Fagron is obligated to produce under Good Manufacturing Practices, or GMP, and to commercialize OMS103 in the U.S. Fagron has not performed its performance diligence obligations under the OMS103 Agreement, including initiating sales, and we are currently evaluating our options regarding the OMS103 Agreement and our OMS103 program.
Product Candidates. We have a pipeline of development programs targeting immune-related disorders, pain, inflammation, coagulopathies and disorders of the central nervous system. We have the following clinical-stage programs in our pipeline:

-12-


MASP-2 - OMS721. OMS721, our lead MASP-2 antibody, is being developed for diseases in which the lectin pathway, one of the principal complement activation pathways, which is believed to contribute to significant tissue injury and pathology. One group of such diseases is thrombotic microangiopathies, or TMAs, including atypical hemolytic uremic syndrome, or aHUS, thrombotic thrombocytopenic purpura, or TTP, and hematopoietic stem-cell transplant, or HSCT, -related TMA. We recently initiated an OMS721 Phase 3 clinical program that consists of one single-arm (i.e., no control arm), open-label trial in patients with newly diagnosed or ongoing aHUS and we expect enrollment will begin later this year. We are also currently conducting two Phase 2 clinical programs, one in patients with other TMAs (i.e., HSCT-related TMA and TTP), as well as a second Phase 2 clinical program in patients with immunoglobulin A, or IgA, nephropathy and other complement-related renal diseases (e.g., membranous nephropathy, lupus nephritis and C3 glomerulopathy) in which we recently initiated patient dosing in a Phase 2 clinical trial in corticosteroid-dependent renal diseases. In addition, in February 2016, we announced that Finnish physicians had requested access to OMS721 under a Special License, granted by the Finnish regulatory authorities, to treat a patient with aHUS who was previously treated with Soliris® (eculizumab) but was determined to not have an adequate response and who was continuing to display signs of active aHUS.
PDE10 - OMS824 for Huntington’s disease and Schizophrenia. OMS824, our lead phosphodiesterase 10, or PDE10, inhibitor, is in a Phase 2 clinical program for the treatment of Huntington’s disease, in which clinical trials are currently subject to dosing limitations, and a Phase 2 clinical program for schizophrenia, in which no clinical trials are currently active. The dosing limitations in our Phase 2 clinical trial in Huntington’s may potentially be removed pending generation, submission and FDA review of additional information. We are conducting nonclinical studies to generate additional data for further discussion with the FDA regarding the dosing limitations and are currently preparing for a re-designed Phase 2 clinical trial in patients with Huntington’s disease. As we announced in October 2014, clinical trials evaluating OMS824 in schizophrenia are suspended currently at the request of the FDA. Given that there was no active schizophrenia trial at the time of program suspension, the FDA will address the OMS824 schizophrenia program when we have a related trial protocol ready for initiation.
PPARγ - OMS405. In our peroxisome proliferator-activated receptor gamma, or PPARγ, program, Phase 2 clinical trials have been conducted by our collaborators to evaluate a PPARγ agonist, alone or in combination with other agents, for treatment of addiction to opioids and to nicotine. Our collaborators are analyzing data from these trials and expect to present relevant information in manuscripts to be published at a later date.
OMS201-Urology. OMS201, our PharmacoSurgery product candidate for use during urological procedures, including uroendoscopic procedures, completed a Phase 1/Phase 2 clinical trial in 2010 and is not currently in active clinical trials.
Development Programs and Platforms. Our preclinical programs and platforms include:
PDE7 - OMS527. In our PDE7 program, we are developing proprietary compounds to treat addiction and compulsive disorders as well as movement disorders.
Plasmin - OMS616. In our Plasmin program, we are advancing novel antifibrinolytic agents for the control of blood loss during surgery or resulting from trauma as well as for other hyperfibrinolytic states (e.g., liver disease).
MASP-3 - OMS906. In our MASP-3 program, OMS906, we are developing MASP-3 inhibitors for the treatment of disorders related to the alternative pathway of the complement system and currently are optimizing potent and functionally active antibodies in preparation for scale-up of one or more clinical candidates.
GPCR Platform and Programs. We have developed a proprietary cellular redistribution assay, or CRA, which we use in a high-throughput manner to identify synthetic ligands, including antagonists, agonists and inverse agonists, that bind to and affect the function of orphan GPCRs. We are conducting in vivo preclinical efficacy studies and optimizing compounds for a number of targets including: GPR17, linked to myelin formation; GPR101, linked to appetite and eating disorders; GPR151, linked to neuropathic pain and cognition; GPR161, which is associated with triple negative breast cancer; GPR183, linked to osteoporosis and to Epstein-Barr virus infections and related diseases; and GPR174, which appears to be involved in the modulation of regulatory T cells, or “T-regs,” known to be important in autoimmune disease, such as multiple sclerosis, and in cancer and organ transplantation.
Antibody Platform. Our proprietary ex vivo platform for the discovery of novel, high-affinity monoclonal antibodies, which was in-licensed from the University of Washington and then further developed by our scientists, utilizes a chicken B-cell lymphoma cell line. We have generated antibodies to several clinically significant targets, including highly potent antibodies against MASP-3, and our platform continues to add to our pipeline antibodies against additional important targets.

-13-


Financial Summary
We recognized net losses of $20.5 million and $18.7 million for the three months ended March 31, 2016 and 2015, respectively. As of March 31, 2016, our accumulated deficit was $423.7 million, total shareholders’ deficit was $40.7 million and we had $13.2 million in cash, cash equivalents and short-term investments available for general corporate use. In addition, we had restricted cash and investments of $10.7 million that we are required to maintain in depository and investment accounts pursuant to (a) our Loan and Security Agreement, or the Oxford/EWB Loan Agreement, with Oxford Finance LLC, or Oxford, and East West Bank, or EWB, and (b) our lease related to the Omeros Building.

Results of Operations
Revenue
Our revenue consists of U.S. product sales of OMIDRIA and revenue recognized in connection with third-party grant funding.
 
Three Months Ended  
 March 31,
 
2016

2015
 
(In thousands)
Product sales, net
$
7,246

 
$
238

Small Business Innovative Research Grants (SBIR)
173

 
150

 Total revenue
$
7,419

 
$
388

The quarterly increase in product sales, net during the three months ended March 31, 2016 compared to the quarterly periods in 2015 was due to the growth in U.S. OMIDRIA sales following our limited product launch in February 2015 and the subsequent broad launch in April 2015. The 9% increase in product sales, net during the three months ended March 31, 2016 compared to the three months ended December 31, 2015 was lower than the growth rate of our prior quarter, which we believe can be attributed to a variety of factors. Effective January 1, 2016, we converted our contract sales force to an in-house sales force, resulting in the replacement of approximately one-third of our previously contracted sales representatives. During January we also hired additional replacement representatives and entered into a commission-only contract sales agent agreement with Precision Lens to cover “square” states in the Midwest that were not covered by our existing sales force. Our newly hired replacement representatives and the Precision Lens representatives completed training programs during January and began making sales calls in early to mid-February, and the average OMIDRIA sales cycle continues to be 10-12 weeks. In addition, January and February have several ophthalmic meetings that are well attended by high-volume cataract surgeons and Medicare data show that the first quarter of any year is generally associated with an 8% reduction in cataract surgery procedures relative to other quarters in the year. While sales were restrained in the first half of the quarter, they subsequently accelerated with March accounting for nearly one half of our first quarter OMIDRIA sales.
Gross-to-Net Deductions
We record OMIDRIA product sales net of estimated chargebacks, rebates, distribution fees and product returns. These deductions are generally referred to as gross-to-net deductions. A summary of our gross-to-net accrual for the three months ended March 31, 2016 is as follows:
 
Chargebacks and Rebates
 
Distribution Fees and Product Return Allowances
 
Total
 
(In thousands)
Balance as of December 31, 2015
$
180

 
$
277

 
$
457

Provision related to current period sales
285

 
268

 
553

Payments made/credits granted
(220
)
 
(189
)
 
(409
)
Balance as of March 31, 2016
$
245

 
$
356

 
$
601

Our overall Omidria gross-to-net deduction for the quarter ended March 31, 2016 was 7.1% of gross product sales.
Chargebacks and Rebates. Subsequent to March 31, 2015, we entered into a variety of agreements including a Pharmaceutical Pricing Agreement, a Federal Supply Schedule, or FSS, agreement, a 340B prime vendor agreement and a Medicaid Drug Rebate Agreement which allow eligible entities to receive discounts on their qualified purchases of OMIDRIA.

-14-


We record a provision for estimated chargebacks and rebates related to these agreements at the time of sale and reduce the accrual when payments are made or credits are granted.
In October 2015, we launched the OMIDRIAssure Reimbursement Services Program to expand patient access to OMIDRIA. We record a provision for estimated OMIDRIAssure claims at the time of sale and reduce the accrual when payments are made.
We expect future chargeback and rebate deductions as a percentage of gross Omidria product sales to increase based on our 340B prime vendor agreement, the increased use of OMIDRIAssure and increased volume of purchases eligible for government-mandated discounts such as 340B and FSS, and rebates.
Distribution Fees and Product Return Allowances. We pay our wholesalers a distribution fee for services they perform for us based on the dollar value of their purchases of OMIDRIA. We record a provision for these charges at the time of sale to the wholesaler and make payments to our wholesalers based on contractual terms.
We allow for the return of product up to 12 months past its expiration date or for product that is damaged or not used by our customers. We record a provision for returns upon sale of OMIDRIA to our wholesaler. When a return or claim is received, we issue a credit memo to the wholesaler against its outstanding receivable to us or reimburse the customer.
We expect distribution fees and product return allowances to correlate to changes in product sales.
Research and Development Expenses
Our research and development expenses can be divided into three categories: direct external expenses, which include clinical research and development and preclinical research and development activities; internal, overhead and other expenses; and stock-based compensation expense. Direct external expenses consist primarily of expenses incurred pursuant to agreements with third-party manufacturing organizations, contract research organizations, or CROs, clinical trial sites, collaborators, licensors and consultants and lab supplies. Costs are reported in preclinical research and development until the program enters the clinic. Internal, overhead and other expenses consist of personnel costs, overhead costs such as rent, utilities and depreciation and other miscellaneous costs. We do not generally allocate our internal resources, employees and infrastructure to any individual research project because we deploy them across multiple clinical and preclinical projects that we are advancing in parallel.
The following table illustrates our expenses associated with these activities:
 
 
Three Months Ended  
 March 31,
 
2016
 
2015
 
(In thousands)
Direct external expenses:
 
Clinical research and development:
 
 
 
OMS721
$
5,996

 
$
1,233

OMIDRIA (OMS302)
1,266

 
754

OMS824
272

 
532

Other clinical programs
15

 
17

Total clinical research and development
7,549

 
2,536

Preclinical research and development
488

 
501

Total direct external expenses
8,037

 
3,037

 
 
 
 
Internal, overhead and other expenses
5,242

 
4,957

Stock-based compensation expense
2,155

 
1,324

Total research and development expenses
$
15,434

 
$
9,318

The increase in total clinical research and development expenses during the three months ended March 31, 2016 compared to the same period in 2015 is due primarily to increased costs for our OMS721 program in connection with clinical manufacturing and other clinical research and development activities. Additional increases included clinical trial costs for OMIDRIA due to continued enrollment and clinical site initiations for the post-approval U.S. pediatric study. This increase was offset by lower clinical research and development costs related to our OMS824 program due to its 2014 clinical suspension.

-15-


In addition, stock-based compensation expenses increased during the three months ended March 31, 2016 compared to the same period in 2015 related to annual company-wide option grants approved in February 2016 with April 1, 2015 vesting commencement dates.
We anticipate that total research and development costs will remain steady or increase slightly during the remainder of this year due to planned clinical manufacturing and clinical study activities relating primarily to OMS721, subject to increases in OMIDRIA product sales and raising of additional funds to support our planned development activities.
At this time, we are unable to estimate with any certainty the costs we will incur in the continued development of our product candidates due to the inherently unpredictable nature of our preclinical and clinical development activities and given the early stage of many of our preclinical development programs. Clinical development timelines, the probability of success and development costs can differ materially as new data become available and as expectations change. While we are focused currently on advancing our product development programs, our future research and development expenses will depend, in part, on the preclinical or clinical success of each product candidate as well as ongoing assessments of each program’s commercial potential. Our future research and development expenses will also be affected by the availability of adequate financial resources and the commercial success of OMIDRIA. In addition, we cannot forecast with any degree of certainty which product candidates, if any, may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.
We are required to expend substantial resources in the development of our product candidates due to the lengthy process of completing clinical trials and seeking regulatory approval. Any failure or delay in completing clinical trials, or in obtaining regulatory approvals, could delay our generation of product revenue and increase our research and development expenses and, in turn, have a material adverse effect on our operations, financial condition and liquidity. Because of the factors above, we are not able to estimate with any certainty when or if we would recognize any net cash inflows from our research and development projects.
Selling, General and Administrative Expenses
 
Three Months Ended  
 March 31,
 
2016
 
2015
 
(In thousands)
Selling, general and administrative expenses, excluding stock-based compensation expense
$
8,843

 
$
7,796

Stock-based compensation expense
2,267


1,193

Total selling, general and administrative expenses
$
11,110

 
$
8,989

The increase in selling, general and administrative expenses during the three months ended March 31, 2016 compared to the same period in 2015 was primarily due to increased legal costs associated with the Par lawsuit, increased administrative costs, and increased selling related activities. The increase in stock-based compensation expense during the three months ended March 31, 2016 compared to the same period in the prior year was due to annual company-wide option grants approved in February 2016 with April 1, 2015 vesting commencement dates.
We anticipate selling, general and administrative costs will increase slightly during the remainder of this year primarily due to commissions on our third party sales agent agreements for OMIDRIA and legal costs in connection with enforcing our patents and pursuing our patent infringement claims related to Par’s effort to obtain FDA approval for a generic version of OMIDRIA.
Interest Expense
 
 
Three Months Ended  
 March 31,
 
2016
 
2015
 
(In thousands)
Interest expense
$
1,375

 
$
957

    

-16-


The increase in interest expense during the three months ended March 31, 2016 compared to the same quarter in the prior year was due to the increase in our outstanding notes payable balance under the Oxford/EWB Loan Agreement during the comparative periods.
Other Income (Expense), Net

 
Three Months Ended  
 March 31,
 
2016
 
2015
 
(In thousands)
Other income (expense), net
$
288


$
218

Other income (expense), net principally includes sublease rental income and interest earned. The increase during the three months ended March 31, 2016 compared to the prior year quarter was due to incremental sublease income earned.

Financial Condition - Liquidity and Capital Resources
As of March 31, 2016, we had $13.2 million in cash, cash equivalents and short-term investments available for general corporate use that are held principally in interest-bearing instruments, including money-market accounts. In addition, we have restricted cash and investments of $10.7 million that we are required to maintain in depository and investment accounts pursuant to (a) our Oxford/EWB Loan Agreement, and (b) our lease related to the Omeros Building. Cash in excess of our immediate requirements is invested in accordance with our established guidelines that are intended to preserve principal and maintain liquidity.

Future Funding Requirements
We have experienced net losses and negative cash flow from operations since inception, and as of March 31, 2016, had an accumulated deficit of $423.7 million, and expect to continue to incur losses until such time as OMIDRIA product sales, corporate partnerships and/or licensing revenues from products or programs are adequate to support our ongoing operating expenses and debt service. As of March 31, 2016 we had unrestricted cash, cash equivalents and short-term investments of $13.2 million. To meet our projected funding requirements through March 31, 2017, we expect to use cash on hand, future OMIDRIA revenues and additional funds we intend to raise through corporate partnerships, through the incurrence of additional debt, through asset sales, through the pursuit of collaborations and licensing arrangements related to certain of our products or programs or through public or private equity securities sales, potentially including our At Market Issuance Sales Agreement, or the ATM Agreement, with JonesTrading Institutional Services LLC, or JonesTrading. Refer to “Liquidity and Capital Resources” within “Item 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the SEC on March 15, 2016, for a description of the ATM Agreement. These conditions raise a substantial doubt about our ability to continue as a going concern. If we are unable to raise additional capital when needed through one or more of the avenues previously listed, or upon acceptable terms, such failure would have a significant negative impact on our financial condition. Should it be necessary to manage our operating expenses, we would reduce our projected cash requirements through reduction of our expenses by delaying clinical trials, reducing selected research and development efforts, or implementing other restructuring activities.
Our independent registered public accounting firm included an explanatory paragraph expressing substantial doubt regarding our ability to continue as a going concern in their report on our consolidated financial statements for the year ended December 31, 2015. A “going concern” opinion means, in general, that our independent registered public accounting firm has substantial doubt about our ability to continue our operations without additional infusions of capital from external sources. Our ability to continue as a going concern depends, in large part, on our ability to generate positive cash flow from operations and obtain additional financing, neither of which is certain. If we are unable to achieve these goals, our business would be jeopardized and we may not be able to continue operations.

-17-


Cash Flow Data
 
Three Months Ended 
 March 31,
 
2016
 
2015
 
(In thousands)
Selected cash flow data
 
 
 
Cash provided by (used in):
 
 
 
Operating activities
$
(16,628
)
 
$
(17,476
)
Investing activities
14,632

 
(62,089
)
Financing activities
1,609

 
80,652

Operating Activities. Net cash used in operating activities was $16.6 million for the three months ended March 31, 2016. The cash used in operating activities was affected by our net loss of $20.5 million, partially offset by stock-based compensation expense of $4.4 million and a $1.5 million increase in inventory. The increase in stock-based compensation expense primarily relates to annual company-wide stock option grants approved in February 2016 with April 1, 2015 vesting commencement dates. The increase in inventory relates to an accumulation of OMIDRIA inventory to ensure adequate commercial supply of OMIDRIA until such time as additional inventory is expected to become available from our new manufacturer in the first part of 2017.

Net cash used in operating activities was $17.5 million for the three months ended March 31, 2015. The cash used in operating activities was affected by a net loss of $18.7 million and a decrease of $2.2 million in accounts payable and accrued expenses, partially offset by stock-based compensation expense of $2.5 million. The change in accounts payable and accrued expenses relates to the timing of operating activities and related payments.
Investing Activities. Cash flows from investing activities primarily reflect cash used to purchase short-term investments and proceeds from the sale of short-term investments, thus causing a shift between our cash and cash equivalents and short-term investment balances. Because we manage our cash usage with respect to our total cash, cash equivalents and short-term investments, we do not consider these fluctuations in cash flows to be important to the understanding of our liquidity and capital resources.
Net cash used in investing activities in the three months ended March 31, 2016 was $14.6 million, an increase of $76.7 million from 2015. The three months ended March 31, 2016 was affected by $14.7 million sales of short-term investments compared to the same period in the prior year that was affected by the purchase of short-term investments with the $79.1 million of net proceeds received from the sale of common stock and pre-funded warrants in our public offering in February 2015. These purchases were partially offset by the sale of $17.3 million of short-term investments to provide cash for operating activities.
Financing Activities. Net cash provided by financing activities in the three months ended March 31, 2016 was $1.6 million, a decrease of $79.0 million over the same period in 2015. Net cash provided by financing activities for the three months ended March 31, 2016 was due to proceeds from the exercise of options and pre-funded warrants, as compared to the same period in 2015 in which cash provided was primarily due to the $79.1 million of net proceeds received from the sale of 3.4 million shares of common stock and pre-funded warrants to purchase 749,250 shares of common stock in our public offering in February 2015 and $1.6 million from proceeds from the exercise of stock options and warrants.

Contractual Obligations and Commitments
Our future minimum contractual commitments and obligations were reported in our Annual Report on Form 10-K for the year ended December 31, 2015 that was filed with the SEC on March 15, 2016. Our future minimum contractual obligations and commitments have not changed materially from the amounts previously reported.
Notes Payable
We have borrowed $50.0 million under the Oxford/EWB Loan Agreement which requires interest-only payments at an annual rate of 9.25% through July 1, 2017. See Note 7 to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the SEC on March 15, 2016, for a description of the Loan Agreement. There was no event of default under the Oxford/EWB Loan Agreement as of March 31, 2016.
Goods & Services
We have entered into an agreement with Hospira Worldwide, Inc., or Hospira, for the ongoing commercial supply of OMIDRIA and we are currently completing the manufacturing process transfer, process validation and approval of Hospira as a

-18-


manufacturing site for OMIDRIA. We anticipate Hospira will be able to provide OMIDRIA commercial product to us beginning in the first part of 2017. We have no firm purchase commitments outstanding under this agreement as of March 31, 2016.
We may also be required, in connection with in-licensing or asset acquisition agreements, to make certain royalty and milestone payments and we cannot, at this time, determine when or if the related milestones will be achieved or whether the events triggering the commencement of payment obligations will occur. See Note 9 to our Consolidated Financial Statements for the year ended December 31, 2015 included in our Annual Report on Form 10-K, as filed with the SEC on March 15, 2016, for a description of the agreements that include these royalty and milestone payment obligations.

Critical Accounting Policies and Significant Judgments and Estimates
The preparation of our condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances; however, actual results could differ from those estimates. An accounting policy is considered critical if it is important to a company’s financial condition and results of operations and if it requires the exercise of significant judgment and the use of estimates on the part of management in its application. Although we believe that our judgments and estimates are appropriate, actual results may differ materially from our estimates.
We believe the judgments, estimates and assumptions associated with the following critical accounting policies have the greatest potential impact on our consolidated financial statements:
Revenue recognition;
Research and development expenses; and
Stock-based compensation.
For a detailed discussion of these critical accounting policies and significant judgments and estimates, refer to “Critical Accounting Policies and Significant Judgments and Estimates” within “Item 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report on Form 10-K for the year ended December 31, 2015 that was filed with the SEC on March 15, 2016. There have not been any material changes in our critical accounting policies and significant judgments and estimates as disclosed in our Annual Report Form 10-K for the year ended December 31, 2015.

Off-Balance Sheet Arrangements
We have not engaged in any off-balance sheet arrangements.


-19-


ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Our exposure to market risk is primarily confined to our investment securities and notes payable. The primary objective of our investment activities is to preserve our capital to fund operations. We also seek to maximize income from our investments without assuming significant risk. To achieve our objectives, we maintain a portfolio of investments in high-credit-quality securities. As of March 31, 2016, we had cash, cash equivalents and short-term investments of $13.2 million. In accordance with our investment policy, we invest funds in highly liquid, investment-grade securities. These securities in our investment portfolio are not leveraged and are classified as available-for-sale. We currently do not hedge interest rate exposure. Because of the short-term maturities of our investments, we do not believe that an increase in market rates would have a material negative impact on the realized value of our investment portfolio. We actively monitor changes in interest rates and, with our current portfolio of short term investments, we are not exposed to potential loss due to changes in interest rates.

ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of March 31, 2016. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of March 31, 2016, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.
Changes in Internal Control over Financial Reporting
There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) under the Exchange Act that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.



-20-


PART II—OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS
In July 2015, we received a Notice Letter from Par Pharmaceutical, Inc. and its subsidiary, Par Sterile Products, LLC, or collectively, Par, that Par filed an Abbreviated New Drug Application, or ANDA, containing a Paragraph IV Certification under the Hatch-Waxman Act and seeking approval from the FDA to market a generic version of OMIDRIA prior to the expiration of three Omeros patents, U.S. Patent Nos. 8,173,707, 8,586,633 and 9,066,856, which relate to OMIDRIA and that are listed in the FDA’s Orange Book for OMIDRIA. These patents were granted following review by the U.S. Patent and Trademark Office, or USPTO, are presumed to be valid under governing law, and can only be invalidated in federal court with clear and convincing evidence. Following receipt of the Paragraph IV Notice Letter we filed a patent infringement lawsuit against Par in the U.S. District Court for the District of New Jersey on September 2, 2015 and a patent infringement lawsuit against Par in the U.S. District Court for the District of Delaware on September 3, 2015. The lawsuits were filed under the Hatch-Waxman Act alleging Par’s infringement of U.S. Patent Nos. 8,173,707, 8,586,633 and 9,066,856. Based on our decision to pursue the action in federal court in Delaware, we voluntarily dismissed the complaint filed in the U.S. District Court for the District of New Jersey. The complaint that we filed in the U.S. District Court for the District of Delaware has been served on Par and Par has filed an answer asserting defenses and counterclaims for declaratory judgment of patent invalidity and non-infringement. In April 2016, we amended the complaint to also assert U.S. Patent No. 9,278,101, which issued in March 2016 and was listed in the Orange Book after Par’s Paragraph IV Notice Letter. Par has filed an answer to our amended complaint asserting defenses and counterclaims for declaratory judgment of patent invalidity and non-infringement. We have reviewed the assertions in Par’s Paragraph IV Notice Letter and believe they do not have merit, and intend to prosecute vigorously our patent infringement claims against Par. Under the Hatch-Waxman Act, we were permitted to file suit within 45 days from receipt of Par’s Notice Letter and thereby trigger a 30-month stay of the FDA’s final approval of Par’s ANDA while the lawsuit against Par is pending. Our lawsuit against Par triggered such a stay, which is expected to remain in effect until late January 2018.

ITEM 1A. RISK FACTORS
The risks and uncertainties described below may have a material adverse effect on our business, prospects, financial condition or operating results. In addition, we may be adversely affected by risks that we currently deem immaterial or by other risks that are not currently known to us. You should carefully consider these risks before making an investment decision. The trading price of our common stock could decline due to any of these risks and you may lose all or part of your investment. In assessing the risks described below, you should also refer to the other information contained in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the year ended December 31, 2015.
Risks Related to Our Products, Programs and Operations
Our ability to achieve profitability is dependent on the commercial success of OMIDRIA. To the extent OMIDRIA is not successful, our business, financial condition and results of operations may be materially adversely affected and the price of our common stock may decline.
OMIDRIA is our only product that has been approved by the FDA for commercial sale in the U.S. For the three months ended March 31, 2016, we recorded net sales of OMIDRIA of $7.2 million. We have not generated revenue from sales of OMIDRIA to date that are sufficient to fund fully our operations and cannot provide assurance that we will generate sufficient revenue from OMIDRIA in the future to fund fully our operations. We will need to generate substantially more product revenue from OMIDRIA to achieve and sustain profitability. Our ability to generate significant revenue from OMIDRIA product sales depends on our ability to achieve increased market acceptance of, and to otherwise market and sell effectively, OMIDRIA, which may not occur for a number of reasons, including:
a lack of acceptance by physicians, patients, government and private payers and other members of the medical community;
our limited experience in marketing, selling and distributing OMIDRIA or any other product;
our limited experience managing third-party commercial manufacturing of OMIDRIA or any other product as well as our limited experience managing and maintaining a commercial sales organization;
pricing, reimbursement and coverage policies of government and private payers such as Medicare, Medicaid, the Department of Veterans Affairs, or VA, group purchasing organizations, insurance companies, health maintenance organizations and other plan administrators;
the availability, relative price and efficacy of the product as compared to alternative treatment options or branded, compounded or generic competing products;

-21-


an unknown safety risk;
the failure to enter into and maintain acceptable partnering arrangements for marketing and distribution of OMIDRIA outside of the U.S.;
changed or increased regulatory restrictions in the U.S., EU and other foreign territories; and
a lack of adequate financial or other resources.
Our operating results are unpredictable and may fluctuate.
Our operating results are difficult to predict and will likely fluctuate from quarter to quarter and year to year. We believe that our quarterly and annual results of operations may be affected by a variety of factors, including:
the level and timing of commercial sales of OMIDRIA as well as our product candidates, if and when approved or commercialized;
the extent of coverage and reimbursement for OMIDRIA, including following the expiration of pass-through reimbursement effective January 1, 2018, and the amount of OMIDRIA chargebacks, rebates and product returns;
the extent of any payments received from collaboration arrangements and development funding as well as the achievement of development and clinical milestones under collaboration and license agreements that we may enter into from time to time and that may vary significantly from quarter to quarter; and
the timing, cost and level of investment in our research and development activities as well as expenditures we will or may incur to acquire or develop additional technologies, products and product candidates.
In addition, the number of procedures in which OMIDRIA or any of our product candidates, if commercialized, would be used may be significantly less than the total number of such procedures performed or total possible market size. These and other factors, including our limited history of product sales, may make it difficult for us to forecast and provide accurate guidance (including updates to prior guidance) related to our expected financial performance. If our operating results are below the expectations of securities analysts or investors, the trading price of our stock could decline.
We have incurred cumulative operating losses since inception. If we are unable to raise additional capital when needed, our commercial operations may be limited and we may be unable to complete the development and commercialization of our product candidates or to continue our other preclinical development programs.
Our operations have consumed substantial amounts of cash since our incorporation and, as of March 31, 2016, we had an accumulated deficit of approximately $423.7 million. We expect to continue to spend substantial amounts to:
continue OMIDRIA sales and marketing;
continue research and development in our programs;
make principal and interest payments under the Oxford/EWB Loan Agreement;
initiate and conduct clinical trials for our programs and product candidates; and
commercialize and launch product candidates for which we may receive regulatory approval.
We expect to continue to incur additional losses until such time as we generate significant revenue from the sale of OMIDRIA, other commercial products and/or significant partnering revenues. We are unable to predict the extent of any future losses and cannot provide assurance that we will generate sufficient revenue from OMIDRIA in the future to fund fully our operations. To date we have not generated revenue from sales of OMIDRIA that is sufficient to fund fully our operations. If we are unable to generate sufficient revenue from the sale of OMIDRIA, other commercialized products and/or partnering arrangements, we may never become and remain profitable and will be required to raise additional capital to continue to fund our operations. We cannot be certain that additional capital will be available to us on acceptable terms, if at all, when required. Adverse developments to our financial condition or business, as well as disruptions in the global equity and credit markets, may limit our ability to access capital. If we do not raise additional capital when needed through one or more funding avenues, such as corporate partnering or debt or equity financings, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our product candidates or one or more of our preclinical programs or other research and development initiatives. In addition, we may be required to seek collaborators for one or more of our current or future products at an earlier stage than otherwise would be desirable or on terms that are less favorable than otherwise might be available or to relinquish or license on unfavorable terms our rights to technologies or products that we otherwise would seek to develop or commercialize ourselves. We also may have insufficient funds or otherwise be unable to advance our preclinical programs, such as potential new drug targets developed from our GPCR program, to a point where they can generate revenue through partnerships, collaborations or other arrangements. Any of these actions could limit the amount of revenue we are able to generate and harm our business and prospects.

-22-


Our independent registered public accounting firm has indicated that our financial condition raises substantial doubt as to our ability to continue as a going concern.
Our financial statements have been prepared assuming that we will continue to operate as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. However, our independent registered public accounting firm has included in its audit opinion for the year ended December 31, 2015 a statement that there is substantial doubt as to our ability to continue as a going concern as a result of our recurring losses and financial condition on December 31, 2015. Our ability to continue as a going concern will require us to generate positive cash flow from operations, obtain additional financing, enter into strategic alliances and/or sell assets. The reaction of investors to the inclusion of a going concern statement by our auditors, our current lack of cash resources and our potential inability to continue as a going concern may materially adversely affect our share price and our ability to raise new capital, enter into strategic alliances and/or make our scheduled debt payments on a timely basis or at all. If we become unable to continue as a going concern, we may have to liquidate our assets and the values we receive for our assets in liquidation or dissolution could be significantly lower than the values reflected in our financial statements.
If OMIDRIA or any other product that we develop and commercialize does not receive adequate reimbursement from governments or private payers, or if we do not establish and maintain market-acceptable pricing for OMIDRIA or those commercialized products, our prospects for revenue and profitability could suffer.
Our future revenues and profitability will depend heavily on the pricing, availability and duration of adequate reimbursement for the use of products that we or our third-party business partners commercialize, including OMIDRIA, from government, private and other third-party payers, both in the U.S. and in other countries. OMIDRIA or any other product that we bring to market may not be considered cost-effective and/or the amount reimbursed for any product may be insufficient to allow us to sell the product profitably. Obtaining reimbursement approval for any product from each government or third-party payer can be a time-consuming and costly process that may require the build-out of a sufficient staff or the engagement of third parties and could require us to provide additional supporting scientific, clinical and cost-effectiveness data for the use of our approved products to each payer. We can provide no assurances at this time regarding the cost-effectiveness of OMIDRIA, OMS103 or any of our product candidates. Further, we can provide no assurance that the amounts, if any, reimbursed to surgical facilities for utilization of any of our surgery-related products, including OMIDRIA, any of our product candidates or OMS103, or to surgeons for the administration and delivery of these products or product candidates will be considered adequate to justify the use of these products or product candidates. In addition, obtaining acceptable coverage and reimbursement from one payer does not guarantee that we will obtain similar acceptable coverage or reimbursement from another payer.
There may be significant delays in obtaining reimbursement for newly approved products, and we may not be able to provide data sufficient to be granted reimbursement. Even when a payer determines that a product is eligible for reimbursement, coverage may be limited to the uses of a product that are either approved by the FDA (or, in other countries, the relevant country’s regulatory agency) and/or appear in a recognized drug compendium, and other conditions may apply. Moreover, eligibility for coverage does not mean that any product will be reimbursed at a rate that allows us to make a profit in all cases or at a rate that covers our costs, including research, development, manufacturing, sales and distribution. Increasingly, government and private third-party payers that reimburse for healthcare services and products are requiring that companies provide them with predetermined discounts from list prices and challenging the prices charged for medical products, which could adversely impact the pricing of our products. Pricing may also be adversely affected by changes in the terms, scope and/or complexity of government pricing requirements. Even if we receive reimbursement for a product, the initial rate or method at which the product will be reimbursed could become unfavorable to us at the time reimbursement is initiated or in the future or may be of a limited duration. After the expiration of pass-through reimbursement status for OMIDRIA effective January 1, 2018, we may not be able to maintain or obtain adequate reimbursement for OMIDRIA.
In non-U.S. jurisdictions, we must obtain separate reimbursement approvals and comply with related foreign legal and regulatory requirements. In some countries, including those in the EU, our products may be subject to government price controls. Pricing negotiations with governmental authorities can take a considerable amount of time and expenditure of resources after the receipt of marketing approval for a product. We provide no assurances that the price of any product in one or more of these countries or regions will allow us to make a profit or cover our costs, including research, development, manufacturing, sales and distribution, and as a result we may decide to delay, potentially indefinitely, initiating sales in the particular country or region.
If the reimbursement or pricing that we are able to obtain and maintain for any product that we develop and commercialize, including OMIDRIA, is inadequate in light of our development and other costs, is significantly delayed or subject to overly restrictive conditions, or is denied by one or more payers, there could be a material adverse effect on our business, financial condition, results of operations and growth prospects.

-23-


We are subject to extensive government regulation and the failure to comply with these regulations may have a material adverse effect on our operations and business.
Both before and after approval of any product, we and our suppliers, contract manufacturers and clinical investigators are subject to extensive regulation by governmental authorities in the U.S. and other countries, covering, among other things, testing, manufacturing, quality control, clinical trials, post-marketing studies, labeling, advertising, promotion, distribution, import and export, governmental pricing, price reporting and rebate requirements. Failure to comply with applicable requirements could result in one or more of the following actions: warning letters; unanticipated expenditures; delays in approval or refusal to approve a product candidate; product recall or seizure; interruption of manufacturing or clinical trials; operating or marketing restrictions; injunctions; criminal prosecution and civil or criminal penalties including fines and other monetary penalties; adverse publicity; and disruptions to our business. Further, government investigations into potential violations of these laws would require us to expend considerable resources and face adverse publicity and the potential disruption of our business even if we are ultimately found not to have committed a violation.
Obtaining FDA approval of our product candidates requires substantial time, effort and financial resources and may be subject to both expected and unforeseen delays, and there can be no assurance that any approval will be granted on any of our product candidates on a timely basis, if at all. Even if we discuss with, and obtain feedback from, the FDA regarding our proposed clinical trials and nonclinical studies before initiating those trials or studies, the FDA may decide that our resulting data are insufficient for approval of our product candidates and require additional preclinical, clinical or other studies or additional work related to chemistry, manufacturing and controls. In addition, we, the FDA or an independent Institutional Review Board or Ethics Committee may suspend or terminate human clinical trials at any time on various grounds, including a finding that the patients are or would be exposed to an unacceptable health risk or because of the way in which the investigators on which we rely carry out the trials. If we are required to conduct additional trials or to conduct other testing of our product candidates beyond that which we currently contemplate for regulatory approval, if we are unable to complete successfully our clinical trials or other testing, or if the results of these and other trials or tests fail to demonstrate efficacy or raise safety concerns, we may face substantial additional expenses, be delayed in obtaining marketing approval for our product candidates or may never obtain marketing approval.
We are also required to comply with extensive governmental regulatory requirements after a product has received marketing authorization. Governing regulatory authorities may require post-marketing studies that may negatively impact the commercial viability of a product. Once on the market, a product may become associated with previously undetected adverse effects and/or may develop manufacturing difficulties. As a result of any of these or other problems, a product’s regulatory approval could be withdrawn, which could harm our business and operating results. In addition, we must establish and maintain an effective healthcare compliance program in order to comply with U.S. and other laws applicable to marketed drug products. U.S. laws such as the Foreign Corrupt Practices Act prohibit the offering or payment of bribes or inducements to foreign public officials, including potentially physicians or other medical professionals who are employees of public health care entities. In addition, many countries have their own laws similar to the healthcare compliance laws that exist in the U.S. Implementing an effective compliance program requires the expenditure of significant time and resources. If we are found to be in violation of any of these laws, we may be subject to significant penalties, including but not limited to civil or criminal penalties, damages and fines as well as exclusion from government healthcare programs.
Failure to obtain regulatory approval in foreign jurisdictions would prevent us from marketing our products internationally.
We intend to have OMIDRIA and our product candidates, if approved, marketed outside the U.S. In order to market our products in non-U.S. jurisdictions, we or our partners must obtain separate regulatory approvals and comply with numerous and varying regulatory requirements. The regulatory approval procedure varies among countries and can involve additional testing and data review. The requirements governing marketing authorization, the conduct of clinical trials, pricing and reimbursement vary from country to country. Approval by the FDA or the European Medicines Agency, or EMA, does not ensure approval by regulatory agencies in other jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory agencies in other foreign countries or by the FDA. The time required to obtain regulatory approval outside the U.S. and EU may differ from that required to obtain FDA or EMA approval. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval discussed in these “Risk Factors” and we may not obtain foreign regulatory approvals on a timely basis, or at all.
If OMIDRIA and/or our product candidates, if approved, are marketed outside of the United States, a variety of risks associated with international operations could materially adversely affect our business.
We may be subject to additional risks if OMIDRIA and/or our product candidates, if approved, are marketed outside the U.S., including:

-24-


reduced protection for intellectual property rights;
unexpected changes in tariffs, trade barriers and regulatory requirements;
economic weakness, including inflation, or political instability in particular foreign economies and markets;
foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country; and
business interruptions resulting from geopolitical actions, including war and terrorism or natural disasters including earthquakes, typhoons, floods and fires.
We currently depend on a third party for the commercialization of OMS103 and we cannot guarantee that such commercialization will occur or be successful.
In June 2015 we entered into the OMS103 Agreement pursuant to which we granted Fagron an exclusive, royalty-free license to the OMS103 intellectual property, manufacturing information and clinical data to manufacture and commercialize OMS103 in the U.S. in exchange for potential future payments based on product revenue and achievement of commercial milestones. As a result of entering into the OMS103 Agreement, we discontinued our OMS103 clinical development program and are dependent on Fagron to commercialize OMS103 in the U.S. We cannot control whether Fagron will fulfill its obligations under the OMS103 Agreement or whether the commercialization of OMS103 will be successful. Fagron has not met the diligence milestones in the OMS103 Agreement, including initiating sales of OMS103, and we are currently evaluating our options with respect to the OMS103 Agreement and the OMS103 program. If we elect to pursue arbitration with Fagron, and/or the OMS103 Agreement is terminated, we can provide no assurances that we will be able to enter into another licensing agreement or have sufficient resources to restart clinical development and conduct any clinical trials if desired. Any of the above risks, if realized, could adversely affect our results of operations.
Under Section 503B of the FDCA, registered outsourcing facilities are required to manufacture under GMP and are subject to FDA inspections and audits. They also are not allowed to manufacture a product that is essentially a copy of one or more FDA-approved drugs. If a licensed registered outsourcing facility such as Fagron is prohibited from commercializing or from continuing commercial sales of OMS103 following initial commercialization because of violations of any FDA regulations or any other reason, our ability to generate revenue from royalty payments from the licensed registered outsourcing facility and achieve profitability will be adversely affected and the market price of our common stock could decline.
We have no internal capacity to manufacture clinical or commercial supplies of OMIDRIA or our product candidates and intend to rely solely on third-party manufacturers. If the contract manufacturers that we rely on experience difficulties manufacturing OMIDRIA or our product candidates or fail FDA or other regulatory inspections, our clinical trials, regulatory submissions and ability to sell OMIDRIA or any other commercialized product and generate revenue may be significantly limited or delayed.
We rely and intend to continue to rely on third party manufacturers to produce commercial quantities of OMIDRIA and clinical drug supplies of our product candidates that are needed for clinical trials. We cannot provide any assurance that we will be able to enter into or maintain these types of arrangements on commercially reasonable terms, or at all. If we or the manufacturer were to terminate one of these arrangements early, or the manufacturer was unable to supply product quantities sufficient to meet our requirements, we would be required to transfer the manufacturing to an approved alternative facility and/or establish additional manufacturing and supply arrangements. We may also need to establish additional or replacement manufacturers, potentially with little or no notice, in the event that one of our manufacturers fails to comply with FDA and/or other pharmaceutical manufacturing regulatory requirements. Even if we are able to establish additional or replacement manufacturers, identifying these sources and entering into definitive supply agreements and obtaining regulatory approvals may require a substantial amount of time and cost and may create a shortage of the product. Such alternate supply arrangements may not be available on commercially reasonable terms, or at all. Additionally, if we are unable to engage multiple suppliers to manufacture our products, we may have inadequate supply to meet the demand of our product.
Our contract manufacturers may encounter difficulties with formulation and manufacturing processes that could result in delays in clinical trials and/or regulatory submissions or that could impact adversely the commercialization of our products or product candidates, as well as in the initiation of enforcement actions by the FDA and other regulatory authorities. These difficulties also could result in the recall or withdrawal of a product from the market or a failure to have adequate supplies to meet market demand. If the safety of OMIDRIA or any product candidate supplied by contract manufacturers is compromised due to one or more of those contract manufacturers’ failure to adhere to applicable laws or for other reasons, we may not be able to maintain regulatory approval of OMIDRIA, to continue sales and marketing of OMIDRIA or to obtain and maintain regulatory approval for one or more of our product candidates, which would harm our business and prospects significantly.

-25-


In addition, any product candidate from our MASP-2, MASP-3 or Plasmin programs could be a biologic drug product, and we do not have the internal capability to produce biologics for use in clinical trials or on a commercial scale. There are only a limited number of manufacturers of biologic drug products and we cannot be certain that we can enter into supply agreements with them on commercially reasonable terms, if at all. Any significant delays in the manufacture of clinical or commercial supplies could materially harm our business, financial condition, results of operations and prospects.
Manufacturing under our existing OMIDRIA manufacturing agreement with Patheon, which is for a specific facility, ceased at the end of 2015. Validation of the manufacturing process for OMIDRIA under our Hospira supply agreement has not been completed. We do not expect that any OMIDRIA manufacturing facility will be approved for production before 2017. We anticipated this transition and increased production of OMIDRIA prior to the break in manufacturing, and believe that we will have sufficient supply to meet product needs until OMIDRIA product production is recommenced. However, we can provide no assurances if or when the Hospira manufacturing facility or a second manufacturing facility for OMIDRIA will be in production or whether we can meet market demand for OMIDRIA if demand is greater than we anticipate. Additionally, damage to or destruction of OMIDRIA inventory, including inventory warehoused at our third-party logistics provider, could also adversely affect our ability to meet market demand. We have obtained insurance coverage for the replacement cost of damaged or destroyed OMIDRIA inventory but such coverage would not compensate us for any resulting loss of sales revenue or a reduction in gross margin.
Ingredients, excipients and other materials necessary to manufacture OMIDRIA or our product candidates may not be available on commercially reasonable terms, or at all, which may adversely affect the development and commercialization of OMIDRIA or those product candidates.
We and our third-party manufacturers must obtain from third-party suppliers the active pharmaceutical ingredients, excipients and primary and secondary packaging materials necessary for our contract manufacturers to produce OMIDRIA and our PharmacoSurgery product candidates for our clinical trials and, to the extent approved or commercialized, for commercial distribution. Although we have entered or intend to enter into agreements with third-party suppliers that will guarantee the availability and timely delivery of active pharmaceutical ingredients, excipients and materials for OMIDRIA and our PharmacoSurgery product candidates, we have not yet entered into agreements for the supply of all such ingredients, excipients or materials, and we may be unable to secure all such supply agreements or guarantees on commercially reasonable terms, if at all. Even if we were able to secure such agreements or guarantees, our suppliers may be unable or choose not to provide us the ingredients, excipients or materials in a timely manner or in the quantities required. If we or our third-party manufacturers are unable to obtain the quantities of these ingredients, excipients or materials that are necessary for the manufacture of commercial supplies of OMIDRIA, our ability to generate revenue from the sale of OMIDRIA would be materially and adversely affected. Further, if we or our third-party manufacturers are unable to obtain active pharmaceutical ingredients, excipients and materials as necessary for our clinical trials or for the manufacture of commercial supplies of our product candidates, if approved, potential regulatory approval or commercialization would be delayed, which would materially and adversely affect our ability to generate revenue from the sale of our product candidates.
If our clinical trials are delayed, suspended or terminated, we may be unable to develop our product candidates on a timely basis, which would adversely affect our ability to obtain regulatory approvals, increase our development costs and delay or prevent commercialization of approved products.
We cannot predict whether we will encounter problems with any of our completed, ongoing or planned clinical trials that will cause regulatory agencies, Institutional Review Boards or Ethics Committees, or us to delay our clinical trials or suspend or delay the analysis of the data from those trials. Clinical trials can be delayed for a variety of reasons, including:
discussions with the FDA, the EMA or other foreign authorities regarding the scope or design of our clinical trials;
delays or the inability to obtain required approvals from Institutional Review Boards, Ethics Committees or other responsible entities at clinical sites selected for participation in our clinical trials;
delays in enrolling patients into clinical trials for any reason including disease severity, trial protocol design, study eligibility criteria, patient population size (e.g., for orphan diseases or for some pediatric indications), proximity and/or availability of clinical trial sites for prospective patients, availability of competing therapies and clinical trials, regional differences in diagnosis and treatment, perceived risks and benefits of the product or product candidate, physician patient referral practices or the ability to monitor patients adequately before and after treatment;
lower than anticipated retention rates of patients in clinical trials;
the need to repeat or conduct additional clinical trials as a result of inconclusive or negative results, failure to replicate positive early clinical data in subsequent clinical trials, poorly executed testing, a failure of a clinical site to adhere to the clinical protocol, an unacceptable study design or other problems;
adverse findings in clinical or nonclinical studies related to the safety of our product candidates in humans;

-26-


an insufficient supply of product candidate materials or other materials necessary to conduct our clinical trials;
the need to qualify new suppliers of product candidate materials for FDA and foreign regulatory approval;
an unfavorable inspection or review by the FDA or other regulatory authority of a clinical trial site or records of any clinical investigation;
the occurrence of unacceptable drug-related side effects or adverse events experienced by participants in our clinical trials;
the suspension by a regulatory agency of a trial put on a clinical hold; and
the amendment of clinical trial protocols to reflect changes in regulatory requirements and guidance or other reasons as well as subsequent re-examination of amendments of clinical trial protocols by Institutional Review Boards or Ethics Committees.
In addition, a clinical trial or development program may be suspended or terminated by us, the FDA or other regulatory authorities, or Institutional Review Boards or Ethics Committees due to a number of factors, including:
failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;
inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;
the failure to remove a clinical hold in a timely manner (which we cannot predict with certainty), if at all;
unforeseen safety issues or any determination that a trial presents unacceptable health risks; or
lack of adequate funding to continue the clinical trial or development program, including the incurrence of unforeseen costs due to enrollment delays, requirements to conduct additional trials and studies and increased expenses associated with the services of our contract research organizations, or CROs, and other third parties.
If the results of our clinical trials are not available when we expect or if we encounter any delay in the analysis of data from our clinical trials, we may be unable to file for regulatory approval or conduct additional clinical trials on the schedule we currently anticipate. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Any delays in completing our clinical trials could increase our development costs, could slow down our product development and regulatory submission process, could delay our receipt of product revenue and could make it difficult to raise additional capital. In addition, significant clinical trial delays also could allow our competitors to bring products to market before we do and impair our ability to commercialize our future products, potentially harming our business.
Because we have a number of product candidates and development programs, we may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications for which there is a greater likelihood of obtaining regulatory approval and that may be more profitable, if approved.
We do not have unlimited resources and must focus on the product candidates and clinical and preclinical development programs that we believe are the most promising. As a result, we may forego or delay the pursuit of opportunities with other product candidates or other indications that later prove to have greater commercial potential and may not be able to progress development programs as rapidly as otherwise possible. Further, if we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product through collaboration, license or other royalty arrangements in cases in which it would have been advantageous for us to retain sole development and commercialization rights.
It is difficult and costly to protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection.
Our commercial success will depend in part on obtaining and maintaining patent protection and trade secret protection for the use, formulation and structure of our products and product candidates, the methods used to manufacture them, the related therapeutic targets and associated methods of treatment as well as on successfully defending these patents against potential third-party challenges. Our ability to protect our products and product candidates from unauthorized making, using, selling, offering to sell or importing by third parties is dependent on the extent to which we have rights under valid and enforceable patents that cover these activities.
The patent positions of pharmaceutical, biotechnology and other life sciences companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. Changes in either the patent laws or in interpretations of patent laws in the U.S. and other countries may diminish the value of our intellectual property. Further, the determination that a patent application or patent claim meets all of the requirements for patentability is a subjective determination based on the application of law and jurisprudence. The ultimate determination by the USPTO or by a

-27-


court or other trier of fact in the U.S., or corresponding foreign national patent offices or courts, on whether a claim meets all requirements of patentability cannot be assured. Although we have conducted searches for third-party publications, patents and other information that may affect the patentability of claims in our various patent applications and patents, we cannot be certain that all relevant information has been identified. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our patents or patent applications, in our licensed patents or patent applications or in third-party patents.
We cannot provide assurances that any of our patent applications will be found to be patentable, including over our own prior art patents, or will issue as patents. Neither can we make assurances as to the scope of any claims that may issue from our pending and future patent applications nor to the outcome of any proceedings by any potential third parties that could challenge the patentability, validity or enforceability of our patents and patent applications in the U.S. or foreign jurisdictions. Any such challenge, if successful, could limit patent protection for our products and product candidates and/or materially harm our business.
The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:
we may not be able to generate sufficient data to support full patent applications that protect the entire breadth of developments in one or more of our programs, including our GPCR program;
it is possible that one or more of our pending patent applications will not become an issued patent or, if issued, that the patent(s) will be sufficient to protect our technology, provide us with a basis for commercially viable products or provide us with any competitive advantages;
if our pending applications issue as patents, they may be challenged by third parties as not infringed, invalid or unenforceable under U.S. or foreign laws; or
if issued, the patents under which we hold rights may not be valid or enforceable.
In addition, to the extent that we are unable to obtain and maintain patent protection for one of our products or product candidates or in the event that such patent protection expires, it may no longer be cost-effective to extend our portfolio by pursuing additional development of a product or product candidate for follow-on indications.
We also may rely on trade secrets to protect our technologies or products, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, outside scientific collaborators and other advisers may unintentionally or willfully disclose our information to competitors. Enforcing a claim that a third-party entity illegally obtained and is using any of our trade secrets is expensive and time-consuming, and the outcome is unpredictable. In addition, courts outside the U.S. are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how.
We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.
If we choose to go to court to stop someone else from using our inventions, that individual or company has the right to ask the court to rule that the underlying patents are invalid or should not be enforced against that third party. These lawsuits are expensive and would consume time and other resources even if we were successful in stopping the infringement of these patents. We expect to incur substantial costs in connection with our lawsuit against Par. In addition, our lawsuit against such an entity could result in a finding that some or all of the claims of one or more of our relevant patents are invalid, unenforceable and/or not infringed, and could also result in a generic version of OMIDRIA being launched after the expiration of the mandatory three-year clinical data exclusivity for OMIDRIA. There is also the risk that, even if the validity of these patents is upheld, the court will refuse to stop the other party on the ground that such other party’s activities do not infringe the patents. An adverse outcome in such legal action could have a material negative effect on our financial condition, results of operations and/or stock price. See “Legal Proceedings” under Item 1 of Part II of this Quarterly Report on Form 10-Q for further discussion of our lawsuit against Par.

-28-


It may not be feasible to detect and undertake patent enforcement action to stop infringing activity by a number of individual entities, each on a small scale, such as compounding pharmacies. Further, our industry has produced a large number of patents and it is not always clear which patents cover various types of products or methods of use. A third party may claim that we or our contract manufacturers are using inventions covered by the third party’s patent rights and may go to court to stop us from engaging in the alleged infringing activity, including making, using or selling our products and product candidates. These lawsuits are costly and could affect our results of operations and divert the attention of managerial and technical personnel. There is a risk that a court would decide that we, or our contract manufacturers, are infringing the third party’s patents and would order us or our contractors to stop the activities covered by the patents. In addition, if we or our contract manufacturers are found to have violated a third party’s patent, we or our contract manufacturers could be ordered to pay damages to the other party. We have agreed to or may agree to indemnify our contract manufacturers against certain patent infringement claims and thus may be responsible for any of their costs associated with such claims and actions. If we were sued for patent infringement, we would need to demonstrate that our products and product candidates or methods of use either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we be unable to do this. Proving invalidity, in particular, is difficult since it requires clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents.
Although we have conducted searches of third-party patents with respect to our programs, we have not obtained written freedom to operate opinions for our programs and may not have identified all relevant third-party patents. Consequently, we cannot be certain that third-party patents containing claims covering our products, product candidates, programs, technologies or methods do not exist, have not been filed, or could not be filed or issued.
Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the capital necessary to continue our operations.
Our competitors may develop products that are less expensive, safer or more effective, or which may otherwise diminish or eliminate the commercial success of any products that we may commercialize.
We may not achieve commercial success if our competitors, many of whom have significantly more resources and experience than we, market products that are safer, more effective, less expensive or faster to reach the market than OMIDRIA or any future products that we may develop and commercialize. Our competitors also may market a product that proves to be unsafe or ineffective, which may affect the market for our competing product, or future product, regardless of the safety or efficacy of our product. The failure of OMIDRIA or any other future product that we may market to effectively compete with products marketed by our competitors would impair our ability to generate revenue, which would have a material adverse effect on our future business, our financial condition and our results of operations.
The loss of members of our management team could substantially disrupt our business operations.
Our success depends to a significant degree on the continued individual and collective contributions of our management team. The members of our management team are at-will employees, and we do not maintain any key-person life insurance policies other than on the life of Gregory A. Demopulos, M.D., our president, chief executive officer and chairman of the board of directors. Losing the services of any key member of our management team, whether from death or disability, retirement, competing offers or other causes, without having a readily available and appropriate replacement could delay the execution of our business strategy, cause us to lose a strategic partner, or otherwise materially affect our operations.
We rely on highly skilled personnel and, if we are unable to retain or motivate key personnel or hire qualified personnel, we may not be able to maintain our operations or grow effectively.
Our performance is largely dependent on the talents and efforts of highly skilled individuals. Our future success depends on our continuing ability to identify, hire, develop, motivate and retain highly skilled personnel for all areas of our organization. If we are unable to hire and train a sufficient number of qualified employees for any reason, we may not be able to implement our current initiatives or grow effectively. We have in the past maintained a rigorous, highly selective and time-consuming hiring process. We believe that our approach to hiring has significantly contributed to our success to date. If we do not succeed in attracting qualified personnel and retaining and motivating existing personnel, our existing operations may suffer and we may be unable to grow effectively.
We may encounter difficulties managing our growth, which could delay our business plans or adversely affect our results of operations.
To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems and continue to recruit and train additional qualified personnel. Due to our limited financial resources, we

-29-


may not be able to manage effectively the expansion of our operations or recruit and train additional qualified personnel. The physical expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. Additionally, our inability to manage growth effectively could cause our operating costs to grow even faster than we currently are anticipating.
Product liability claims may damage our reputation and, if insurance proves inadequate, these claims may harm our business.
We may be exposed to the risk of product liability claims that is inherent in the biopharmaceutical industry. A product liability claim may damage our reputation by raising questions about our product’s safety and efficacy and could limit our ability to sell one or more products by preventing or interfering with commercialization of our products and product candidates. In addition, product liability insurance for the biopharmaceutical industry is generally expensive to the extent it is available at all. There can be no assurance that we will be able to obtain or maintain such insurance on acceptable terms or that we will be able to secure and maintain increased coverage if the commercialization of OMIDRIA or our product candidates progresses, or that future claims against us will be covered by our product liability insurance. Further, our product liability insurance coverage may not reimburse us or may be insufficient to reimburse us for any or all expenses or losses we may suffer. A successful claim against us with respect to uninsured liabilities or in excess of insurance coverage could have a material adverse effect on our business, financial condition and results of operations.
Our preclinical programs may not produce product candidates that are suitable for clinical trials or that can be successfully commercialized or generate revenue through partnerships.
We must complete successfully preclinical testing, which may include demonstrating efficacy and the lack of toxicity in established animal models, before commencing clinical trials for any product candidate. Many pharmaceutical and biological products do not successfully complete preclinical testing and, even if preclinical testing is successfully completed, may fail in clinical trials. In addition, there can be no assurance that positive results from preclinical studies will be predictive of results obtained from subsequent preclinical studies or clinical trials. We also cannot be certain that any product candidates that do advance into clinical trials will successfully demonstrate safety and efficacy in clinical trials. Even if we achieve positive results in early clinical trials, they may not be predictive of the results in later trials.
We rely on third parties to conduct portions of our preclinical research and clinical trials. If these third parties do not perform as contractually required or otherwise expected, or if we fail to adequately supervise or monitor these parties, we may not be able to obtain regulatory approval for or commercialize our product candidates.
We rely on third parties, such as CROs, medical and research institutions and clinical investigators, to conduct a portion of our preclinical research and assist us in conducting our clinical trials. Nonetheless, we are responsible for confirming that our preclinical research and clinical trials are conducted in accordance with applicable regulations, the relevant trial protocol and within the context of approvals by an Institutional Review Board or Ethics Committee, and we may not always be successful in ensuring such compliance. Our reliance on these third parties does not relieve us of responsibility for ensuring compliance with FDA and other regulations and standards for conducting, monitoring, recording and reporting the results of preclinical research and clinical trials to assure that data and reported results are credible and accurate and that the trial participants are adequately protected. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, if the third parties need to be replaced or if the quality or accuracy of the data they obtain is compromised due to their failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our preclinical and clinical development processes may be extended, delayed, suspended or terminated, and we may not be able to commercialize or obtain regulatory approval for our product candidates.
We may need to maintain licenses for active ingredients from third parties to develop and commercialize some of our product candidates, which could increase our development costs and delay our ability to commercialize those product candidates.
Should we decide to use active pharmaceutical ingredients in any of our product candidates that are proprietary to one or more third parties, such as our PDE7 program (OMS527) or our plasmin program (OMS616), we would need to maintain licenses to those active ingredients from those third parties. If we are unable to continue to access rights to these active ingredients prior to conducting preclinical toxicology studies intended to support clinical trials, we may need to develop alternate product candidates from these programs by either accessing or developing alternate active ingredients, resulting in increased development costs and delays in commercialization of these product candidates. If we are unable to maintain continued access rights to the desired active ingredients on commercially reasonable terms or develop suitable alternate active ingredients, we may not be able to commercialize product candidates from these programs.

-30-


The terms of our debt facility place restrictions on our operating and financial flexibility and, if we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business.
We have borrowed $50.0 million under the Oxford/EWB Loan Agreement. As collateral for this loan, we pledged substantially all of our assets other than intellectual property (with the exception of the proceeds derived from any intellectual property). The Oxford/EWB Loan Agreement restricts our ability to, among other things, incur indebtedness, grant liens, dispose of assets, make investments, make acquisitions, enter into certain transactions with affiliates, pay dividends or make distributions, repurchase stock, license our intellectual property for a limited set of our programs without lender approval, pledge our intellectual property and engage in significant business transactions such as a change of control. Any of these restrictions could significantly limit our operating and financial flexibility and ability to respond to changes in our business or competitive activities. The Oxford/EWB Loan Agreement also requires us to achieve certain minimum net revenue amounts from OMIDRIA through the end of 2018, including achieving net revenues of at least $70.0 million for the 2016 calendar year, and to maintain at least $10.0 million in cash and cash equivalents during the term of the Oxford/EWB Loan Agreement. The failure to satisfy these or other obligations under the Oxford/EWB Loan Agreement would allow the lenders to declare a default. If we default under the Oxford/EWB Loan Agreement, the lenders may have the right to accelerate all of our repayment obligations under the Oxford/EWB Loan Agreement and to take control of our pledged assets, which include our cash, cash equivalents and short-term investments. Further, if we are liquidated, the lenders’ right to repayment would be senior to the rights of the holders of our common stock to receive any proceeds from the liquidation. An event of default under the Oxford/EWB Loan Agreement includes the occurrence of any material adverse effect upon our business operations, properties, assets, results of operations or financial condition, taken as a whole with respect to our viability, that would reasonably be expected to result in our inability to repay the loan. If either lender declares all obligations under the Oxford/EWB Loan Agreement immediately due and payable upon the occurrence of any event that the lender interprets as constituting an event of default as defined under the Oxford/EWB Loan Agreement, including but not limited to the lender concluding that a material adverse change has occurred as defined under the Oxford/EWB Loan Agreement, we will be required to repay the loan immediately or to attempt to reverse the declaration through negotiation or litigation. Any declaration of an event of default could significantly harm our business and prospects and could cause our stock price to decline. If we raise any additional debt financing, the terms of such debt could further restrict our operating and financial flexibility.
We use hazardous materials in our business and must comply with environmental laws and regulations, which can be expensive.
Our research operations produce hazardous waste products, which include chemicals and radioactive and biological materials. We are subject to a variety of federal, state and local regulations relating to the use, handling, storage and disposal of these materials. Although we believe that our safety procedures for handling and disposing of these materials comply with applicable legal regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. We generally contract with third parties for the disposal of such substances and store our low-level radioactive waste at our facility until the materials are no longer considered radioactive. We may be required to incur further costs to comply with current or future environmental and safety regulations. In addition, although we carry insurance, in the event of accidental contamination or injury from these materials, we could be held liable for any damages that result and any such liability could exceed our insurance coverage and other resources.
Cyber-attacks or other failures in telecommunications or information technology systems could result in information theft, data corruption and significant disruption of our business operations.
We utilize information technology, or IT, systems and networks to process, transmit and store electronic information in connection with our business activities. As use of digital technologies has increased, cyber incidents, including deliberate attacks and attempts to gain unauthorized access to computer systems and networks, have increased in frequency and sophistication. These threats pose a risk to the security of our systems and networks, the confidentiality and the availability and integrity of our data. There can be no assurance that we will be successful in preventing cyber-attacks or successfully mitigating their effects. Similarly, there can be no assurance that our collaborators, CROs, third-party logistics providers, distributors and other contractors and consultants will be successful in protecting our clinical and other data that is stored on their systems. Any cyber-attack or destruction or loss of data could have a material adverse effect on our business and prospects. In addition, we may suffer reputational harm or face litigation or adverse regulatory action as a result of cyber-attacks or other data security breaches and may incur significant additional expense to implement further data protection measures.

-31-


Risks Related to Our Common Stock
Our stock price has been and may continue to be volatile, and the value of an investment in our common stock may decline.
During the 12-month period ended March 31, 2016, our stock traded as high as $30.23 per share and as low as $8.90 per share. The trading price of our common stock is likely to continue to be highly volatile and could be subject to wide fluctuations in response to numerous factors, many of which are beyond our control. In addition, the stock market has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of publicly traded companies. Broad market and industry factors may seriously affect the market price of companies’ stock, including ours, regardless of actual operating performance. These fluctuations may be even more pronounced in the trading market for our stock. In addition, in the past, following periods of volatility in the overall market and the market price of a particular company’s securities, securities class action litigation has often been instituted against these companies. This litigation, if instituted against us, could result in substantial costs and a diversion of our management’s attention and resources.
If we issue additional shares of our common stock or other securities that may be convertible into, or exercisable or exchangeable for, our common stock, our existing shareholders would experience further dilution.
To the extent that we raise additional funds by issuing equity securities, including pursuant to our ATM Agreement with JonesTrading, our shareholders would experience dilution, which may be significant and could cause the market price of our common stock to decline significantly. In addition, approximately 9.5 million shares of common stock as of May 2, 2016 subject to outstanding options may become eligible for sale in the public market to the extent permitted by the provisions of various vesting agreements. Further, as of May 2, 2016 we also had approximately 1.9 million shares of common stock reserved for future issuance under our employee benefit plans that are not subject to outstanding options. If the holders of these outstanding options to purchase our common stock elect to exercise some or all of them, or if the shares subject to our employee benefit plans are issued and become eligible for sale in the public market, our shareholders would experience dilution and the market price of our common stock could decline.
Anti-takeover provisions in our charter documents and under Washington law could make an acquisition of us, which may be beneficial to our shareholders, difficult and prevent attempts by our shareholders to replace or remove our current management.
Provisions in our articles of incorporation and bylaws and under Washington law may delay or prevent an acquisition of us or a change in our management. These provisions include a classified board of directors, a prohibition on shareholder actions by less than unanimous written consent, restrictions on the ability of shareholders to fill board vacancies and the ability of our board of directors to issue preferred stock without shareholder approval. In addition, because we are incorporated in Washington, we are governed by the provisions of Chapter 23B.19 of the Washington Business Corporation Act, which, among other things, restricts the ability of shareholders owning 10% or more of our outstanding voting stock from merging or combining with us. Although we believe these provisions collectively provide for an opportunity to receive higher bids by requiring potential acquirers to negotiate with our board of directors, they would apply even if an offer may be considered beneficial by some shareholders. In addition, these provisions may frustrate or prevent any attempts by our shareholders to replace or remove our current management by making it difficult for shareholders to replace members of our board of directors, which is responsible for appointing the members of our management.
We have never declared or paid dividends on our capital stock, and we do not anticipate paying dividends in the foreseeable future.
Our business requires significant funding. We currently plan to invest all available funds and future earnings, if any, in the development and growth of our business. Additionally, under the Oxford/EWB Loan Agreement, we have agreed not to pay any dividends. Therefore, we currently do not anticipate paying any cash dividends on our common stock in the foreseeable future. As a result, a rise in the market price of our common stock, which is uncertain and unpredictable, will be the sole source of potential gain for shareholders in the foreseeable future, and an investment in our common stock for dividend income should not be relied upon.

-32-


ITEM 6. EXHIBITS
 
Exhibit
Number
Description
12.1
Ratio of Earnings to Fixed Charges
31.1
Certification of Principal Executive Officer Pursuant to Rule 13-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2
Certification of Principal Financial Officer Pursuant to Rule 13-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1
Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2
Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS
XBRL Instance Document
101.SCH
XBRL Taxonomy Extension Schema Document
101.CAL
XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF
XBRL Taxonomy Extension Definition Linkbase Document
101.LAB
XBRL Taxonomy Extension Label Linkbase Document
101.PRE
XBRL Taxonomy Extension Presentation Linkbase Document



-33-


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
OMEROS CORPORATION
 
 
Dated: May 10, 2016
/s/ Gregory A. Demopulos
 
Gregory A. Demopulos, M.D.
 
President, Chief Executive Officer and Chairman of the Board of Directors
 
 
Dated: May 10, 2016
/s/ Michael A. Jacobsen
 
Michael A. Jacobsen
 
Vice President, Finance, Chief Accounting Officer and Treasurer

-34-
EX-12.1 2 ex121_2016331.htm EXHIBIT 12.1 SEC Exhibit


 
 
 
 
 
EXHIBIT 12.1
 
 
 
 
 
Omeros Corporation
Computation of Deficiency in the Coverage of Fixed Charges by Earnings Before Fixed Charges
 
 
 
 
 
 
 
 
 
For the
 
 
 
three months
 
 
 
ended
 
 
 
March 31,
 
 
 
Year Ended December 31,
 
2016
 
2015
 
2014
 
2013
 
2012
 
2011
 
(in thousands)
 
(in thousands)
Earnings before fixed charges:
 
 
 
 
 
 
 
 
 
 
Loss from continuing operations before income taxes
$
(20,539
)
 
$
(75,096
)
 
$
(73,673
)
 
$
(39,796
)
 
$
(38,444
)
 
$
(28,546
)
Add fixed charges
2,211

 
8,295

 
6,824

 
5,621

 
2,305

 
2,144

Add amortization of capitalized interest

 

 

 

 

 

Add distributed income of equity investees

 

 

 

 

 

Subtract capitalized interest

 

 

 

 

 

Loss before fixed charges
$
(18,328
)
 
$
(66,801
)
 
$
(66,849
)
 
$
(34,175
)
 
$
(36,139
)
 
$
(26,402
)
Fixed Charges:
 
 
 
 
 
 
 
 
 
 
 
Interest expense
$
1,161

 
$
2,709

 
$
2,710

 
$
1,865

 
$
1,355

 
$
1,532

Amortization of debt expense and loss from extinguishment of debt
213

 
2,177

 
759

 
502

 
374

 
352

Estimate of interest expense within rental expense
837

 
3,409

 
3,355

 
3,254

 
576

 
260

Preference security dividend requirements of consolidated subsidiaries

 

 

 

 

 

Total fixed charges
$
2,211

 
$
8,295

 
$
6,824

 
$
5,621

 
$
2,305

 
$
2,144

Deficiency of earnings available to cover fixed charges
$
(20,539
)
 
$
(75,096
)
 
$
(73,673
)
 
$
(39,796
)
 
$
(38,444
)
 
$
(28,546
)




EX-31.1 3 ex311_2016331.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULE 13a-14(a)/15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Gregory A. Demopulos, M.D., certify that:
1.
I have reviewed this quarterly report on Form 10-Q of Omeros Corporation;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 
Dated: May 10, 2016
 
 
 
/s/ Gregory A. Demopulos
 
Gregory A. Demopulos, M.D.
Principal Executive Officer


EX-31.2 4 ex312_2016331.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13a-14(a)/15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Michael A. Jacobsen, certify that:
1.
I have reviewed this quarterly report on Form 10-Q of Omeros Corporation;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 
Dated: May 10, 2016
 
 
 
/s/ Michael A. Jacobsen
 
Michael A. Jacobsen
 
Principal Financial and Accounting Officer


EX-32.1 5 ex321_2016331.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Omeros Corporation (the “Company”) for the quarter ended March 31, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in such filing.
 
 
Dated: May 10, 2016
 
 
 
/s/ Gregory A. Demopulos
 
Gregory A. Demopulos, M.D.
 
Principal Executive Officer


EX-32.2 6 ex322_2016331.htm EXHIBIT 32.2 Exhibit


Exhibit 32.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Omeros Corporation (the “Company”) for the quarter ended March 31, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in such filing.
 
 
Dated: May 10, 2016
 
 
 
/s/ Michael A. Jacobsen
 
Michael A. Jacobsen
 
Principal Financial and Accounting Officer


EX-101.INS 7 omer-20160331.xml XBRL INSTANCE DOCUMENT 0001285819 2016-01-01 2016-03-31 0001285819 2016-05-02 0001285819 2016-03-31 0001285819 2015-12-31 0001285819 2015-01-01 2015-03-31 0001285819 2015-03-31 0001285819 2014-12-31 0001285819 us-gaap:CashMember 2016-03-31 0001285819 omer:CashandEligibleInvestmentsMember 2016-03-31 0001285819 us-gaap:AccountingStandardsUpdate201503Member 2015-01-01 2015-03-31 0001285819 us-gaap:WarrantMember 2015-01-01 2015-03-31 0001285819 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-03-31 0001285819 us-gaap:WarrantMember 2016-01-01 2016-03-31 0001285819 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-03-31 0001285819 omer:RestrictedCashNoncurrentMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0001285819 omer:RestrictedCashNoncurrentMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0001285819 omer:RestrictedCashNoncurrentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0001285819 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0001285819 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0001285819 us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0001285819 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0001285819 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0001285819 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0001285819 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0001285819 omer:RestrictedCashNoncurrentMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0001285819 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0001285819 omer:RestrictedCashNoncurrentMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0001285819 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0001285819 us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0001285819 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0001285819 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0001285819 omer:RestrictedCashNoncurrentMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0001285819 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0001285819 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0001285819 omer:RestrictedCashNoncurrentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0001285819 omer:RestrictedCashNoncurrentMember us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0001285819 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0001285819 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0001285819 2015-01-01 2015-12-31 0001285819 omer:OxfordEWBLoanMember 2016-03-31 0001285819 omer:OxfordEWBLoanMember 2015-12-31 0001285819 omer:OxfordEWBLoanMember 2015-01-01 2015-12-31 0001285819 us-gaap:WeightedAverageMember 2016-03-31 0001285819 2015-02-01 2015-02-28 0001285819 omer:PrefundedWarrantsMember 2015-02-28 0001285819 2015-02-28 0001285819 omer:AtTheMarketATMProgramMember 2016-01-31 0001285819 omer:AtTheMarketATMProgramMember 2016-01-01 2016-03-31 0001285819 us-gaap:StockOptionMember us-gaap:WeightedAverageMember 2015-01-01 2015-03-31 0001285819 us-gaap:StockOptionMember 2015-01-01 2015-03-31 0001285819 us-gaap:StockOptionMember 2016-01-01 2016-03-31 0001285819 us-gaap:StockOptionMember us-gaap:WeightedAverageMember 2016-01-01 2016-03-31 0001285819 us-gaap:EmployeeStockOptionMember 2016-02-01 2016-02-29 0001285819 omer:EquityIncentivePlanTwentyZeroEightMember 2016-03-31 0001285819 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-03-31 0001285819 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-01-01 2016-03-31 0001285819 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-01-01 2015-03-31 0001285819 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-03-31 omer:segment iso4217:USD xbrli:shares xbrli:shares xbrli:pure omer:tranche iso4217:USD false --12-31 Q1 2016 2016-03-31 10-Q 0001285819 39135054 Accelerated Filer OMEROS CORP OMER 1108000 2061000 2973000 3260000 0.05 126000 100000000 70000000 10000000 0.5 20000000 10000000 2 10679000 0 0 10679000 26898000 0 0 26898000 10679000 0 0 10679000 12266000 0 0 12266000 1576000 1609000 0.017 P0Y0M10D 6428000 5332000 9752000 12120000 2400000 3232000 376528000 382548000 1324000 1193000 2155000 2267000 9526529 8365741 1160788 9302348 9302348 0 48995000 35972000 37146000 24322000 37577000 0 0 37577000 22945000 0 0 22945000 26898000 12266000 1400000 978000 354000 1441000 1365000 978000 1087000 -387000 13200000 0.01 0.01 749250 0.01 0.01 150000000 150000000 38040891 39119154 38040891 39119154 380000 391000 -18669000 -20539000 11000 327000 50000000 3600000 414000 9207000 9220000 55000 53000 -0.51 -0.54 2590000 2544000 16600000 8989000 11110000 -2170000 226000 1272000 0 1500000 -725000 -226000 420000 146000 129000 957000 1375000 745000 776000 221000 176000 472000 1972000 93000 104000 158000 1692000 48995000 35972000 16253000 17521000 73000 69000 49769000 49973000 80652000 1609000 -62089000 14632000 -17476000 -16628000 -18669000 -20539000 1 18318000 26871000 -17930000 -19452000 681000 1023000 219000 73000 218000 288000 212000 213000 4900000 79389000 18000 0.01 0.01 20000000 20000000 0 0 0 0 0 0 1894000 2460000 79100000 79076000 0 17300000 14650000 1400000 7500 951000 898000 6517000 6646000 9318000 15434000 10679000 10679000 10000000 679000 -403142000 -423681000 150000 173000 388000 7419000 238000 7246000 2517000 4422000 0.00 0.00 0.0151 0.0144 0.70 0.74 2189575 6486712 7.09 27929 14.51 1269055 1349055 13.49 6.62 65720000 8310235 9302348 7.97 8.40 64505000 9012412 8.30 4.87 10.27 10.31 20.03 20.02 P6Y0M18D P5Y8M26D 53722000 P5Y5M30D P6Y5M45D P6Y5M15D 3400000 749250 329013 -26234000 -40742000 0 0 36483559 38317084 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:174%;padding-top:18px;text-align:left;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:inherit;font-size:10pt;">$13.2 million</font><font style="font-family:inherit;font-size:10pt;"> in cash, cash equivalents and short-term investments. In addition, we have $</font><font style="font-family:inherit;font-size:10pt;">10.0 million</font><font style="font-family:inherit;font-size:10pt;"> in restricted cash and investments that must be maintained in depository and investment accounts pursuant to the Loan and Security Agreement (the Oxford/EWB Loan Agreement) entered into in December 2015 with Oxford Finance LLC (Oxford) and East West Bank (EWB) as well as </font><font style="font-family:inherit;font-size:10pt;">$679,000</font><font style="font-family:inherit;font-size:10pt;"> used to secure a letter of credit for the Omeros Building lease. We expect to continue to incur losses until such time as OMIDRIA product sales, corporate partnerships and/or licensing revenues from products or programs are adequate to support our ongoing operating expenses and debt service. We are unable to predict if or when this may occur, and until it does occur, we will need to continue to raise additional funds through public or private equity securities sales, including under our At Market Issuance Sales Agreement (the ATM Agreement) with JonesTrading Institutional Services LLC (JonesTrading) (see Note 9 for further detail), through the incurrence of additional debt, through corporate partnerships, through asset sales or through the pursuit of collaborations and licensing arrangements related to certain of our products or programs. These conditions raise a substantial doubt about our ability to continue as a going concern. If we are unable to become cash-flow positive or to raise additional capital as and when needed, or upon acceptable terms, such failure would have a significant negative impact on our financial condition. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. &#160;The accompanying unaudited condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to our ability to continue as a going concern. </font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our condensed consolidated financial statements include the financial position and results of operations of Omeros Corporation (Omeros) and our wholly owned subsidiaries. All inter-company transactions have been eliminated and we have determined we operate in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> segment. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. The information as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;"> includes all adjustments, which include normal recurring adjustments, necessary to present fairly our interim financial information. The Condensed Consolidated Balance Sheet at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> has been derived from our audited financial statements but does not include all of the information and footnotes required by GAAP.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements and related notes thereto should be read in conjunction with the audited consolidated financial statements and related notes thereto that are included within our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, which was filed with the U.S. Securities and Exchange Commission (SEC) on March 15, 2016.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash, Cash Equivalents and Investments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, all investments are classified as short-term and available-for-sale on the accompanying Condensed Consolidated Balance Sheets. We did not own any securities with unrealized loss positions as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">. Investment income, which is included as a component of other income (expense), consists of interest earned.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Development Milestones and Product Royalties</font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have retained control of worldwide commercial rights to OMIDRIA, to all of our product candidates and to our programs other than OMS103. We may be required, in connection with existing in-licensing or asset acquisition agreements, to make certain royalty and milestone payments and we cannot, at this time, determine when or if the related milestones will be achieved or whether the events triggering the commencement of payment obligations will occur. See Note 9 to our Consolidated Financial Statements for the year ended December 31, 2015 included within our Annual Report on Form&#160;10-K as filed with the SEC on March 15, 2016.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Litigation</font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As described within Note 9 of the &#8220;Notes to Consolidated Financial Statements&#8221; included within our Annual Report on Form 10-K for the year ended December 31, 2015 filed with the SEC on March 15, 2016, we filed a patent infringement lawsuit against Par Pharmaceutical, Inc. and its subsidiary, Par Sterile Products, LLC (collectively, Par) following our receipt of a Paragraph IV Notice Letter from Par stating Par is seeking approval from the FDA to market a generic version of OMIDRIA. During 2016, we amended the lawsuit asserting an additional OMIDRIA patent, which was granted by the U.S. Patent and Trademark Office after Par filed its original Paragraph IV Notice Letter. We have filed suit against Par, thereby triggering a stay which is expected to remain in effect until January 2018 of the FDA&#8217;s final approval of Par&#8217;s ANDA. We continue to believe that the assertions in Par&#8217;s Paragraph IV Notice Letter do not have merit and we intend to prosecute vigorously our patent infringement claims against Par.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes Payable</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2015, we entered into the Oxford/EWB Loan Agreement pursuant to which we borrowed </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;">. We can also borrow an additional </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> in </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> tranches of </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> each through June 30, 2017, contingent upon the satisfaction of certain conditions including minimum net revenues from OMIDRIA. The Oxford/EWB Loan Agreement requires interest-only payments through July&#160;1, 2017. Beginning in August 2017, principal and interest payments are due through the January&#160;1, 2020 maturity date.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Oxford/EWB Loan Agreement contains covenants that require us to maintain </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> in restricted cash and certain eligible term investments and limit or restrict our ability to enter into certain transactions. In addition, we are required to either meet an annual OMIDRIA net revenue minimum for 2016 of </font><font style="font-family:inherit;font-size:10pt;">$70.0 million</font><font style="font-family:inherit;font-size:10pt;"> and quarterly OMIDRIA revenue minimums in 2017 and 2018, or maintain </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> of the then-outstanding note payable balance in restricted cash and certain eligible term investments. The Oxford/EWB Loan Agreement also includes provisions related to events of default, the occurrence of a material adverse effect (MAE) and changes of control. The occurrence of an event of default could result in the acceleration of the Oxford/EWB Loan Agreement and, under certain circumstances, could increase our interest rate by </font><font style="font-family:inherit;font-size:10pt;">5.0%</font><font style="font-family:inherit;font-size:10pt;"> per annum during the period of default. There was no event of default under the Oxford/EWB Loan Agreement as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the remaining unamortized discount and debt issuance costs associated with the debt were </font><font style="font-family:inherit;font-size:10pt;">$3.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$414,000</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense includes amortization of stock options granted to employees and non-employees and has been reported in our Condensed Consolidated Statements of Operations and Comprehensive Loss as follows:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:76%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended &#160;<br clear="none"/>&#160;March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,155</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,324</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,267</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,193</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,422</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,517</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, in connection with our annual employee review process, we granted qualified employees options to purchase approximately&#160;</font><font style="font-family:inherit;font-size:10pt;">1.3 million</font><font style="font-family:inherit;font-size:10pt;">&#160;shares of our common stock with an exercise price of&#160;</font><font style="font-family:inherit;font-size:10pt;">$10.27</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of each option grant to employees and directors is estimated on the date of grant using the Black-Scholes option-pricing model. The following assumptions were applied to employee and director stock option grants during the periods ended:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:76%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended &#160;<br clear="none"/>&#160;March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated weighted-average fair value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-average assumptions</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term, in years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock option activity for all stock plans and related information is as follows:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price per</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual&#160;Life</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In&#160;thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,310,235</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.97</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,349,055</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(329,013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.87</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,929</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.51</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at March 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,302,348</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.40</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,720</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest at March 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,012,412</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.30</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.46</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,505</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at March 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,486,712</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.09</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,722</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, excluding non-employee stock options, the total estimated compensation expense to be recognized in connection with our unvested options is </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$16.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2,189,575</font><font style="font-family:inherit;font-size:10pt;"> shares were available to grant.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Loss Per Share</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common share equivalents outstanding for the period, determined using the treasury-stock method. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The basic and diluted net loss per share amounts for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;"> were computed based on the shares of common stock outstanding during the respective periods. Potentially dilutive securities excluded from the diluted loss per share calculation are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:74%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding options to purchase common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,302,348</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,365,741</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants and pre-funded warrants to purchase common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,160,788</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,302,348</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,526,529</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our fair value hierarchy for our financial assets and liabilities measured at fair value on a recurring basis are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money-market funds classified as non-current restricted cash and investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,679</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,679</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money-market funds classified as short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,266</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,266</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,945</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,945</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money-market funds classified as non-current restricted cash and investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,679</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,679</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money-market funds classified as short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,898</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,898</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,577</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,577</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair-Value Measurements</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On a recurring basis, we measure certain financial assets at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The accounting standard establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required:</font></div><div style="line-height:120%;padding-top:6px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;1&#8212;Observable inputs for identical assets or liabilities, such as quoted prices in active markets;</font></div><div style="line-height:120%;padding-top:6px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;2&#8212;Inputs other than quoted prices in active markets that are either directly or indirectly observable;&#160;and</font></div><div style="line-height:120%;padding-top:6px;padding-left:120px;text-indent:-54px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;3&#8212;Unobservable inputs in which little or no market data exists, therefore they are developed using estimates and assumptions developed by us, which reflect those that a market participant would use.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our fair value hierarchy for our financial assets and liabilities measured at fair value on a recurring basis are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money-market funds classified as non-current restricted cash and investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,679</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,679</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money-market funds classified as short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,266</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,266</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,945</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,945</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money-market funds classified as non-current restricted cash and investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,679</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,679</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money-market funds classified as short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,898</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,898</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,577</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,577</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash held in demand deposit accounts of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$978,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.4</font><font style="font-family:inherit;font-size:10pt;"> million is excluded from our fair-value hierarchy disclosure as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> unrealized gains and losses associated with our short-term investments as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">. The carrying amounts reported in the accompanying Condensed Consolidated Balance Sheets for receivables, accounts payable and other current monetary assets and liabilities approximate fair value because of the immediate or short-term maturity of these financial instruments.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inventory</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of inventory are as follows:</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:74%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March&#160;31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work-in-process</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,692</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">158</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">176</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">221</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,972</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">472</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work-in-process consists of manufactured vials of OMIDRIA which have not been packaged into finished goods.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Organization</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Our first drug product OMIDRIA was approved by the United States (U.S.) Food and Drug Administration (FDA) for use during cataract surgery or intraocular lens replacement. We broadly launched OMIDRIA in the U.S. in April 2015.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Adopted Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the year ended December 31, 2015 we adopted and applied retrospectively Financial Accounting Standards Board (FASB) Accounting Standards Update, or ASU, No. 2015-03, related to simplifying the presentation of debt issuance costs. This standard requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction to the liability. The adoption of ASU 2015-03 resulted in the reclassification of </font><font style="font-family:inherit;font-size:10pt;">$226,000</font><font style="font-family:inherit;font-size:10pt;"> of debt issuance costs in our March 31, 2015 Condensed Consolidated Statement of Cash Flows. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, FASB issued ASU 2016-02 related to lease accounting. This standard requires lessees to recognize a right-of-use asset and a lease liability for most leases. This standard must be applied using a modified retrospective transition and is effective for all annual and interim periods beginning after December 15, 2018. Earlier adoption is permitted. We are evaluating how this new standard will impact the presentation of our financial statements and related disclosures.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, FASB issued ASU 2016-08 related to revenue recognition. This standard is an amendment to ASU 2014-09 relating to revenue from contracts with customers. This amendment clarifies an entity&#8217;s revenue recognition for a performance obligation based on principal versus agent considerations. This standard must be applied retroactively to each prior reporting period presented or retrospectively with the cumulative effect of applying the standard recognized in the period adopted. As amended, the standard is effective for interim and annual periods beginning after December 15, 2017 and cannot be adopted before that effective date. We are currently evaluating the impact that this standard may have on our financial statements once it is adopted.</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU 2016-09 that changes the accounting for certain aspects of share-based payments to employees. The guidance requires the recognition of the income tax effects of awards in the income statement when the awards vest or are settled, thus eliminating additional paid in capital pools. The guidance also allows for the employer to repurchase more of an employee&#8217;s shares for tax withholding purposes without triggering liability accounting and for making a policy election to account for forfeitures as they occur rather than on an estimated basis. The guidance is effective for interim and annual periods beginning after December 15, 2016 with early adoption permitted. We are currently evaluating the impact that this standard may have on our financial statements once it is adopted and the timing of adoption.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization and Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Organization</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Our first drug product OMIDRIA was approved by the United States (U.S.) Food and Drug Administration (FDA) for use during cataract surgery or intraocular lens replacement. We broadly launched OMIDRIA in the U.S. in April 2015.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our condensed consolidated financial statements include the financial position and results of operations of Omeros Corporation (Omeros) and our wholly owned subsidiaries. All inter-company transactions have been eliminated and we have determined we operate in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> segment. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. The information as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;"> includes all adjustments, which include normal recurring adjustments, necessary to present fairly our interim financial information. The Condensed Consolidated Balance Sheet at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> has been derived from our audited financial statements but does not include all of the information and footnotes required by GAAP.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements and related notes thereto should be read in conjunction with the audited consolidated financial statements and related notes thereto that are included within our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, which was filed with the U.S. Securities and Exchange Commission (SEC) on March 15, 2016.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Sales, Net</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We record revenue from OMIDRIA product sales when the product is delivered to our wholesalers.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product sales are recorded net of estimated chargebacks and rebates, wholesaler distribution fees and estimated product returns. Accruals or allowances are established for these deductions when revenue is recognized, and actual amounts incurred are offset against the applicable accruals and allowances. We reflect each of these accruals or allowances as either a reduction in the related accounts receivable or as an accrued liability, depending on how the accrual or allowance is settled. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant items subject to such estimates include revenue recognition, fair market value of investments, stock-based compensation expense and accruals for clinical trials and contingencies. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances; however, actual results could differ from these estimates.</font></div><div style="line-height:174%;padding-top:18px;text-align:left;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:inherit;font-size:10pt;">$13.2 million</font><font style="font-family:inherit;font-size:10pt;"> in cash, cash equivalents and short-term investments. In addition, we have $</font><font style="font-family:inherit;font-size:10pt;">10.0 million</font><font style="font-family:inherit;font-size:10pt;"> in restricted cash and investments that must be maintained in depository and investment accounts pursuant to the Loan and Security Agreement (the Oxford/EWB Loan Agreement) entered into in December 2015 with Oxford Finance LLC (Oxford) and East West Bank (EWB) as well as </font><font style="font-family:inherit;font-size:10pt;">$679,000</font><font style="font-family:inherit;font-size:10pt;"> used to secure a letter of credit for the Omeros Building lease. We expect to continue to incur losses until such time as OMIDRIA product sales, corporate partnerships and/or licensing revenues from products or programs are adequate to support our ongoing operating expenses and debt service. We are unable to predict if or when this may occur, and until it does occur, we will need to continue to raise additional funds through public or private equity securities sales, including under our At Market Issuance Sales Agreement (the ATM Agreement) with JonesTrading Institutional Services LLC (JonesTrading) (see Note 9 for further detail), through the incurrence of additional debt, through corporate partnerships, through asset sales or through the pursuit of collaborations and licensing arrangements related to certain of our products or programs. These conditions raise a substantial doubt about our ability to continue as a going concern. If we are unable to become cash-flow positive or to raise additional capital as and when needed, or upon acceptable terms, such failure would have a significant negative impact on our financial condition. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. &#160;The accompanying unaudited condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to our ability to continue as a going concern. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Adopted Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the year ended December 31, 2015 we adopted and applied retrospectively Financial Accounting Standards Board (FASB) Accounting Standards Update, or ASU, No. 2015-03, related to simplifying the presentation of debt issuance costs. This standard requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction to the liability. The adoption of ASU 2015-03 resulted in the reclassification of </font><font style="font-family:inherit;font-size:10pt;">$226,000</font><font style="font-family:inherit;font-size:10pt;"> of debt issuance costs in our March 31, 2015 Condensed Consolidated Statement of Cash Flows. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, FASB issued ASU 2016-02 related to lease accounting. This standard requires lessees to recognize a right-of-use asset and a lease liability for most leases. This standard must be applied using a modified retrospective transition and is effective for all annual and interim periods beginning after December 15, 2018. Earlier adoption is permitted. We are evaluating how this new standard will impact the presentation of our financial statements and related disclosures.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, FASB issued ASU 2016-08 related to revenue recognition. This standard is an amendment to ASU 2014-09 relating to revenue from contracts with customers. This amendment clarifies an entity&#8217;s revenue recognition for a performance obligation based on principal versus agent considerations. This standard must be applied retroactively to each prior reporting period presented or retrospectively with the cumulative effect of applying the standard recognized in the period adopted. As amended, the standard is effective for interim and annual periods beginning after December 15, 2017 and cannot be adopted before that effective date. We are currently evaluating the impact that this standard may have on our financial statements once it is adopted.</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU 2016-09 that changes the accounting for certain aspects of share-based payments to employees. The guidance requires the recognition of the income tax effects of awards in the income statement when the awards vest or are settled, thus eliminating additional paid in capital pools. The guidance also allows for the employer to repurchase more of an employee&#8217;s shares for tax withholding purposes without triggering liability accounting and for making a policy election to account for forfeitures as they occur rather than on an estimated basis. The guidance is effective for interim and annual periods beginning after December 15, 2016 with early adoption permitted. We are currently evaluating the impact that this standard may have on our financial statements once it is adopted and the timing of adoption.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Sales, Net</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We record revenue from OMIDRIA product sales when the product is delivered to our wholesalers.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product sales are recorded net of estimated chargebacks and rebates, wholesaler distribution fees and estimated product returns. Accruals or allowances are established for these deductions when revenue is recognized, and actual amounts incurred are offset against the applicable accruals and allowances. We reflect each of these accruals or allowances as either a reduction in the related accounts receivable or as an accrued liability, depending on how the accrual or allowance is settled. </font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities consisted of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:74%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,260</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,973</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consulting and professional fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,232</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,400</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,544</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trials</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,061</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,108</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accruals</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">681</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total accrued liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,120</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,752</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Potentially dilutive securities excluded from the diluted loss per share calculation are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:74%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding options to purchase common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,302,348</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,365,741</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants and pre-funded warrants to purchase common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,160,788</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,302,348</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,526,529</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense includes amortization of stock options granted to employees and non-employees and has been reported in our Condensed Consolidated Statements of Operations and Comprehensive Loss as follows:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:76%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended &#160;<br clear="none"/>&#160;March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,155</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,324</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,267</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,193</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,422</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,517</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">he components of inventory are as follows:</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:74%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March&#160;31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work-in-process</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,692</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">158</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">176</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">221</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,972</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">472</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock option activity for all stock plans and related information is as follows:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price per</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual&#160;Life</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In&#160;thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,310,235</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.97</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,349,055</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(329,013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.87</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,929</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.51</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at March 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,302,348</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.40</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,720</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest at March 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,012,412</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.30</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.46</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,505</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at March 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,486,712</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.09</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,722</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following assumptions were applied to employee and director stock option grants during the periods ended:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:76%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended &#160;<br clear="none"/>&#160;March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated weighted-average fair value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-average assumptions</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term, in years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shareholders&#8217; Equity</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">At Market Issuance Sales Agreement</font><font style="font-family:inherit;font-size:10pt;"> - In January 2016, we entered into the ATM Agreement with JonesTrading pursuant to which we may direct JonesTrading to sell shares of our common stock with an aggregate offering price of up to </font><font style="font-family:inherit;font-size:10pt;">$100.0 million</font><font style="font-family:inherit;font-size:10pt;"> directly on The Nasdaq Global Market, through a market maker other than on an exchange or in negotiated transactions. Any sales made under the ATM Agreement are based solely on our instructions and JonesTrading will receive a </font><font style="font-family:inherit;font-size:10pt;">1.7%</font><font style="font-family:inherit;font-size:10pt;"> commission from the gross proceeds. The ATM Agreement may be terminated by either party at any time upon </font><font style="font-family:inherit;font-size:10pt;">10 days</font><font style="font-family:inherit;font-size:10pt;">' notice to the other party or by JonesTrading at any time in certain circumstances including the occurrence of a material adverse effect to Omeros. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Securities Offering</font><font style="font-family:inherit;font-size:10pt;"> - In February 2015, we sold </font><font style="font-family:inherit;font-size:10pt;">3.4 million</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock at a public offering price of </font><font style="font-family:inherit;font-size:10pt;">$20.03</font><font style="font-family:inherit;font-size:10pt;"> per share and sold pre-funded warrants to purchase up to </font><font style="font-family:inherit;font-size:10pt;">749,250</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock at a public offering price of </font><font style="font-family:inherit;font-size:10pt;">$20.02</font><font style="font-family:inherit;font-size:10pt;"> per pre-funded warrant share. The public offering price for the pre-funded warrants was equal to the public offering price of our common stock, less the </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;"> per share exercise price of each pre-funded warrant. After deducting underwriter discounts and offering expenses of </font><font style="font-family:inherit;font-size:10pt;">$4.9 million</font><font style="font-family:inherit;font-size:10pt;">, we received net proceeds from the offering of </font><font style="font-family:inherit;font-size:10pt;">$79.1 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Warrants</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, we received cash proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">$7,500</font><font style="font-family:inherit;font-size:10pt;"> upon the cash exercise of our then-outstanding pre-funded warrants, which had a weighted average exercise price of </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;"> per share, that resulted in the issuance of </font><font style="font-family:inherit;font-size:10pt;">749,250</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three months ended March 31, 2015, we received proceeds of </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;"> upon the exercise of warrants to purchase approximately </font><font style="font-family:inherit;font-size:10pt;">126,000</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accrued Liabilities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities consisted of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:74%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,260</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,973</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consulting and professional fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,232</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,400</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,544</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trials</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,061</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,108</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accruals</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">681</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total accrued liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,120</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,752</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant items subject to such estimates include revenue recognition, fair market value of investments, stock-based compensation expense and accruals for clinical trials and contingencies. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances; however, actual results could differ from these estimates.</font></div></div> EX-101.SCH 8 omer-20160331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2110100 - Disclosure - Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Accrued Liabilities - Accrued Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Cash, Cash Equivalents and Investments link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Fair-Value Measurements link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Fair-Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Fair-Value Measurements - Narrative (Detail) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Fair-Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Inventory (Notes) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Net Loss Per Share - Calculation of Historical Outstanding Dilutive Securities Not Included in Diluted Loss Per Share (Detail) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 2412401 - Disclosure - Notes Payable (Detail) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Organization and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2401402 - Disclosure - Organization and Significant Accounting Policies (Detail) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Organization and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Shareholders' Equity (Detail) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2416404 - Disclosure - Stock-Based Compensation - Fair Value of Employee Option Grant Estimated on Date of Grant (Details) link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - Stock-Based Compensation - Narrative (Detail) link:presentationLink link:calculationLink link:definitionLink 2416403 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail) link:presentationLink link:calculationLink link:definitionLink 2416405 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity and Related Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 omer-20160331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 omer-20160331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 omer-20160331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Equity [Abstract] Shareholders' Equity Stockholders' Equity Note Disclosure [Text Block] Earnings Per Share [Abstract] Calculation of Historical Outstanding Dilutive Securities Not Included in Diluted Loss per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Fair Value Disclosures [Abstract] Financial Assets and Liabilities Measured at Fair Value on Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Statement of Financial Position [Abstract] Statement [Table] Statement [Table] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Statement [Line Items] Statement [Line Items] Assets Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Short-term investments Available-for-sale Securities, Equity Securities, Current Receivables Receivables, Net, Current Inventory Inventory, Net Prepaid expense Prepaid Expense, Current Total current assets Assets, Current Property and equipment, net Property, Plant and Equipment, Net Restricted cash and investments Restricted Cash and Cash Equivalents, Noncurrent Other assets Other Assets, Noncurrent Total assets Assets Liabilities and shareholders’ deficit Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued expenses Accrued Liabilities, Current Current portion of notes payable Long-term Debt, Current Maturities Total current liabilities Liabilities, Current Notes payable, net Long-term Debt, Excluding Current Maturities Deferred rent Deferred Rent Credit, Noncurrent Commitments and contingencies (Note 8) Commitments and Contingencies Shareholders’ deficit: Stockholders' Equity Attributable to Parent [Abstract] Preferred stock, par value $0.01 per share, 20,000,000 authorized and none issued and outstanding at March 31, 2016 and December 31, 2015 Preferred Stock, Value, Issued Common stock, par value $0.01 per share, 150,000,000 authorized at March 31, 2016 and December 31, 2015; 39,119,154 and 38,040,891 issued and outstanding at March 31, 2016 and December 31, 2015, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Accumulated deficit Retained Earnings (Accumulated Deficit) Total shareholders’ deficit Stockholders' Equity Attributable to Parent Total liabilities and shareholders’ deficit Liabilities and Equity Inventory Disclosure [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves Work-in-process Inventory, Work in Process, Net of Reserves Finished goods Inventory, Finished Goods, Net of Reserves Inventory Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Outstanding options to purchase common stock Employee Stock Option [Member] Warrants and pre-funded warrants to purchase common stock Warrant [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Outstanding dilutive securities not included in diluted loss per share calculation Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Debt Disclosure [Abstract] Notes Payable Debt Disclosure [Text Block] Accounting Policies [Abstract] Restricted Cash and Cash Equivalents [Axis] Restricted Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Cash and Eligible Investments Cash and Eligible Investments [Member] Cash and Eligible Investments [Member] Cash Cash [Member] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2015-03 Accounting Standards Update 2015-03 [Member] Increase (decrease) in prepaid expenses and other noncurrent assets Increase (Decrease) in Prepaid Expense and Other Assets Increase (decrease) in accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Number of operating segments Number of Operating Segments Cash, cash equivalents and short-term investments Cash, Cash Equivalents, and Short-term Investments Restricted cash and investments Restricted Cash and Investments, Noncurrent Unamortized balance of debt issuance costs Debt Issuance Costs, Net Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Oxford EWB Loan Oxford EWB Loan [Member] Oxford EWB Loan [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Loan and security agreement, existing outstanding indebtedness Long-term Debt, Gross Line of credit, accordion feature, limit increase Line of Credit Facility, Accordion Feature, Increase Limit Line of Credit Facility, Accordion Feature, Increase Limit Line of credit, accordion feature, number of tranches Line of Credit Facility, Accordion Feature, Increase Limit, Number of Tranches Line of Credit Facility, Accordion Feature, Increase Limit, Number of Tranches Line of credit, accordion feature, increase per tranche Line of Credit Facility, Accordion Feature, Increase Limit, Increase Per Tranche Line of Credit Facility, Accordion Feature, Increase Limit, Increase Per Tranche Debt instrument, covenant compliance, restricted cash and certain eligible term investments Debt Instrument, Covenant Compliance, Minimum Restricted Cash and Certain Eligible Term Investments Threshold Debt Instrument, Covenant Compliance, Minimum Restricted Cash and Certain Eligible Term Investments Threshold Debt instrument, covenant compliance, minimum annual net revenue requirements Debt Instrument, Covenant Compliance, Minimum Annual Net Revenue Requirement Debt Instrument, Covenant Compliance, Minimum Annual Net Revenue Requirement Debt instrument, covenant compliance, minimum restricted cash and eligible term investments as a percent of outstanding balance Debt Instrument, Covenant Compliance, Minimum Restricted Cash and Eligible Term Investments as a Percent of Outstanding Balance Debt Instrument, Covenant Compliance, Minimum Restricted Cash and Eligible Term Investments as a Percent of Outstanding Balance Potential additional default interest Additional Default Interest Rate Additional Default Interest Rate Unamortized balance of debt discount Debt Instrument, Unamortized Discount Income Statement [Abstract] Product sales, net Sales Revenue, Goods, Net Grant revenue Revenue from Grants Revenue Revenues Costs and expenses Operating Expenses [Abstract] Cost of product sales Cost of Goods Sold Research and development Research and Development Expense Selling, general and administrative General and Administrative Expense Total costs and expenses Operating Expenses Loss from operations Operating Income (Loss) Interest expense Interest Expense Other income (expense), net Other Nonoperating Income (Expense) Net loss Net Income (Loss) Attributable to Parent Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Basic and diluted net loss per share (USD per share) Earnings Per Share, Basic and Diluted Weighted-average shares used to compute basic and diluted net loss per share (shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Fair Value, Assets and Liabilities Measured on Recurring Basis [Table] Fair Value Assets And Liabilities Measured On Recurring Basis [Table] Fair Value, Assets and Liabilities Measured on Recurring Basis [Table] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value, Measurements, Recurring Fair Value, Measurements, Recurring [Member] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value, Inputs, Level 1 Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 Fair Value, Inputs, Level 3 [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Restricted Cash, Noncurrent Restricted Cash, Noncurrent [Member] Restricted Cash, Noncurrent [Member] Short-term Investments Short-term Investments [Member] Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] Money-market funds, fair value disclosure Money-Market Funds, Fair Value Disclosure Money-Market Funds, Fair Value Disclosure Total Assets, Fair Value Disclosure Cash and Cash Equivalents [Abstract] Cash, Cash Equivalents and Investments Cash, Cash Equivalents, and Short-term Investments [Text Block] Statement of Cash Flows [Abstract] Operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net loss Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Stock-based compensation expense Share-based Compensation Non-cash interest expense Paid-in-Kind Interest Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Receivables Increase (Decrease) in Receivables Inventory Increase (Decrease) in Inventories Prepaid expenses and other noncurrent assets Accounts payable and accrued expenses Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of investments Payments to Acquire Available-for-sale Securities Proceeds from the sale and maturities of investments Proceeds from Sale of Available-for-sale Securities Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from issuance of common stock and pre-funded warrants, net Proceeds from Issuance of Common Stock Proceeds upon exercise of stock options and warrants Proceeds from Stock Options and Warrants Exercised Proceeds from Stock Options and Warrants Exercised Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Net (decrease) increase in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental cash flow information Supplemental Cash Flow Information [Abstract] Cash paid for interest Interest Paid Fair-Value Measurements Fair Value Disclosures [Text Block] Organization and Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Inventory Inventory Disclosure [Text Block] Payables and Accruals [Abstract] Accrued Liabilities Supplemental Balance Sheet Disclosures [Text Block] Contract research and development Accrued Contract Research Costs Accrued preclinical research and development contract costs. Consulting and professional fees Accrued Professional Fees, Current Employee compensation Employee-related Liabilities, Current Clinical trials Accrued Clinical Trial Costs Accrued clinical trial costs. Other accruals Other Accrued Liabilities, Current Total accrued liabilities Organization Nature of Operations [Text Block] Revenue Recognition Revenue Recognition, Sales of Goods [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Equity Option Equity Option [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Weighted Average Weighted Average [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Estimated weighted-average fair value (USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Expected term, in years Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Stock-Based Compensation Expense Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Stock Option Activity and Related Information Schedule of Share-based Compensation, Activity [Table Text Block] Net Loss Per Share Earnings Per Share [Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Cash excluded from fair value hierarchy disclosure Cash Unrealized gain (loss) on investments Unrealized Gain (Loss) on Investments Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] At The Market (ATM) Program [Member] At The Market (ATM) Program [Member] At The Market (ATM) Program [Member] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Pre-funded Warrants Pre-funded Warrants [Member] Pre-funded Warrants [Member] Class of Stock [Line Items] Class of Stock [Line Items] Common Stock Value Authorized under Stock Offering Program Common Stock Value Authorized under Stock Offering Program Common Stock Value Authorized under Stock Offering Program Stock issued during period Stock Issued During Period, Shares, New Issues Share price (in USD per share) Share Price Shares of common stock to purchase by warrant Class of Warrant or Right, Number of Securities Called by Warrants or Rights Exercise price of warrants (in USD per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Offering expenses and underwriter discounts Payments of Stock Issuance Costs Proceeds from warrant exercises Proceeds from Warrant Exercises Stock Issued During Period, Shares, Other Stock Issued During Period, Shares, Other Warrants exercised during period Class of Warrant or Right, Exercised During Period Class of Warrant or Right, Exercised During Period Stock Offering Program, Commission Percent Stock Offering Program, Commission Percent Stock Offering Program, Commission Percent Stock Offering Program, Notice Period for Termination Stock Offering Program, Notice Period for Termination Stock Offering Program, Notice Period for Termination Document Documentand Entity Information [Abstract] Document Documentand Entity Information [Abstract] Entities [Table] Entities [Table] Document Information [Line Items] Document Information [Line Items] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Stock options Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Equity Incentive Plan 2008 Equity Incentive Plan Twenty Zero Eight [Member] Equity Incentive Plan Twenty Zero Eight [Member] Granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Granted (USD per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Unrecognized compensation expense Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Shares available for future grants Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Preferred stock, par value (USD per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, authorized shares Preferred Stock, Shares Authorized Preferred stock, Issued shares Preferred Stock, Shares Issued Preferred stock, outstanding shares Preferred Stock, Shares Outstanding Common stock, par value (USD per share) Common Stock, Par or Stated Value Per Share Common stock, authorized shares Common Stock, Shares Authorized Common stock, Issued shares Common Stock, Shares, Issued Common stock, outstanding shares Common Stock, Shares, Outstanding Schedule of Inventory, Current Schedule of Inventory, Current [Table Text Block] Options Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Beginning balance (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Exercised (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Forfeited (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Ending balance (shares) Vested and expected to vest (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Exercisable (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Weighted-Average Exercise Price per Share Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Beginning balance (USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Exercised (USD per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Forfeited (USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Ending balance (USD per share) Vested and expected to vest (USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Exercisable (USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted- Average Remaining Contractual Life Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract] Balance (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Vested and expected to vest (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Exercisable (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract] Balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Vested and expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Stock-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Research and Development Expense Research and Development Expense [Member] Selling, General and Administrative Expenses Selling, General and Administrative Expenses [Member] Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Stock-based compensation expense Allocated Share-based Compensation Expense Total EX-101.PRE 12 omer-20160331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 13 R1.htm IDEA: XBRL DOCUMENT v3.4.0.3
Document and Entity Information - shares
3 Months Ended
Mar. 31, 2016
May. 02, 2016
Document Information [Line Items]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Mar. 31, 2016  
Document Fiscal Year Focus 2016  
Document Fiscal Period Focus Q1  
Trading Symbol OMER  
Entity Registrant Name OMEROS CORP  
Entity Central Index Key 0001285819  
Current Fiscal Year End Date --12-31  
Entity Filer Category Accelerated Filer  
Entity Common Stock, Shares Outstanding   39,135,054
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.4.0.3
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 978 $ 1,365
Short-term investments 12,266 26,898
Receivables 6,646 6,517
Inventory 1,972 472
Prepaid expense 2,460 1,894
Total current assets 24,322 37,146
Property and equipment, net 898 951
Restricted cash and investments 10,679 10,679
Other assets 73 219
Total assets 35,972 48,995
Current liabilities:    
Accounts payable 5,332 6,428
Accrued expenses 12,120 9,752
Current portion of notes payable 69 73
Total current liabilities 17,521 16,253
Notes payable, net 49,973 49,769
Deferred rent $ 9,220 $ 9,207
Commitments and contingencies (Note 8)
Shareholders’ deficit:    
Preferred stock, par value $0.01 per share, 20,000,000 authorized and none issued and outstanding at March 31, 2016 and December 31, 2015 $ 0 $ 0
Common stock, par value $0.01 per share, 150,000,000 authorized at March 31, 2016 and December 31, 2015; 39,119,154 and 38,040,891 issued and outstanding at March 31, 2016 and December 31, 2015, respectively 391 380
Additional paid-in capital 382,548 376,528
Accumulated deficit (423,681) (403,142)
Total shareholders’ deficit (40,742) (26,234)
Total liabilities and shareholders’ deficit $ 35,972 $ 48,995
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.4.0.3
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Mar. 31, 2016
Dec. 31, 2015
Preferred stock, par value (USD per share) $ 0.01 $ 0.01
Preferred stock, authorized shares 20,000,000 20,000,000
Preferred stock, Issued shares 0 0
Preferred stock, outstanding shares 0 0
Common stock, par value (USD per share) $ 0.01 $ 0.01
Common stock, authorized shares 150,000,000 150,000,000
Common stock, Issued shares 39,119,154 38,040,891
Common stock, outstanding shares 39,119,154 38,040,891
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.4.0.3
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Product sales, net $ 7,246 $ 238
Grant revenue 173 150
Revenue 7,419 388
Costs and expenses    
Cost of product sales 327 11
Research and development 15,434 9,318
Selling, general and administrative 11,110 8,989
Total costs and expenses 26,871 18,318
Loss from operations (19,452) (17,930)
Interest expense (1,375) (957)
Other income (expense), net 288 218
Net loss (20,539) (18,669)
Comprehensive loss $ (20,539) $ (18,669)
Basic and diluted net loss per share (USD per share) $ (0.54) $ (0.51)
Weighted-average shares used to compute basic and diluted net loss per share (shares) 38,317,084 36,483,559
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.4.0.3
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Operating activities:    
Net loss $ (20,539) $ (18,669)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 53 55
Stock-based compensation expense 4,422 2,517
Non-cash interest expense 213 212
Changes in operating assets and liabilities:    
Receivables (129) (146)
Inventory (1,500) 0
Prepaid expenses and other noncurrent assets (420) 725
Accounts payable and accrued expenses 1,272 (2,170)
Net cash used in operating activities (16,628) (17,476)
Investing activities:    
Purchases of investments (18) (79,389)
Proceeds from the sale and maturities of investments 14,650 17,300
Net cash provided by (used in) investing activities 14,632 (62,089)
Financing activities:    
Proceeds from issuance of common stock and pre-funded warrants, net 0 79,076
Proceeds upon exercise of stock options and warrants 1,609 1,576
Net cash provided by financing activities 1,609 80,652
Net (decrease) increase in cash and cash equivalents (387) 1,087
Cash and cash equivalents at beginning of period 1,365 354
Cash and cash equivalents at end of period 978 1,441
Supplemental cash flow information    
Cash paid for interest $ 776 $ 745
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.4.0.3
Organization and Significant Accounting Policies
3 Months Ended
Mar. 31, 2016
Accounting Policies [Abstract]  
Organization and Significant Accounting Policies
Organization and Significant Accounting Policies
Organization
We are a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Our first drug product OMIDRIA was approved by the United States (U.S.) Food and Drug Administration (FDA) for use during cataract surgery or intraocular lens replacement. We broadly launched OMIDRIA in the U.S. in April 2015.
Basis of Presentation
Our condensed consolidated financial statements include the financial position and results of operations of Omeros Corporation (Omeros) and our wholly owned subsidiaries. All inter-company transactions have been eliminated and we have determined we operate in one segment. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. The information as of March 31, 2016 and for the three months ended March 31, 2016 and 2015 includes all adjustments, which include normal recurring adjustments, necessary to present fairly our interim financial information. The Condensed Consolidated Balance Sheet at December 31, 2015 has been derived from our audited financial statements but does not include all of the information and footnotes required by GAAP.
The accompanying unaudited condensed consolidated financial statements and related notes thereto should be read in conjunction with the audited consolidated financial statements and related notes thereto that are included within our Annual Report on Form 10-K for the year ended December 31, 2015, which was filed with the U.S. Securities and Exchange Commission (SEC) on March 15, 2016.
Product Sales, Net
We record revenue from OMIDRIA product sales when the product is delivered to our wholesalers.
Product sales are recorded net of estimated chargebacks and rebates, wholesaler distribution fees and estimated product returns. Accruals or allowances are established for these deductions when revenue is recognized, and actual amounts incurred are offset against the applicable accruals and allowances. We reflect each of these accruals or allowances as either a reduction in the related accounts receivable or as an accrued liability, depending on how the accrual or allowance is settled.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant items subject to such estimates include revenue recognition, fair market value of investments, stock-based compensation expense and accruals for clinical trials and contingencies. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances; however, actual results could differ from these estimates.
Liquidity and Capital Resources
As of March 31, 2016, we had $13.2 million in cash, cash equivalents and short-term investments. In addition, we have $10.0 million in restricted cash and investments that must be maintained in depository and investment accounts pursuant to the Loan and Security Agreement (the Oxford/EWB Loan Agreement) entered into in December 2015 with Oxford Finance LLC (Oxford) and East West Bank (EWB) as well as $679,000 used to secure a letter of credit for the Omeros Building lease. We expect to continue to incur losses until such time as OMIDRIA product sales, corporate partnerships and/or licensing revenues from products or programs are adequate to support our ongoing operating expenses and debt service. We are unable to predict if or when this may occur, and until it does occur, we will need to continue to raise additional funds through public or private equity securities sales, including under our At Market Issuance Sales Agreement (the ATM Agreement) with JonesTrading Institutional Services LLC (JonesTrading) (see Note 9 for further detail), through the incurrence of additional debt, through corporate partnerships, through asset sales or through the pursuit of collaborations and licensing arrangements related to certain of our products or programs. These conditions raise a substantial doubt about our ability to continue as a going concern. If we are unable to become cash-flow positive or to raise additional capital as and when needed, or upon acceptable terms, such failure would have a significant negative impact on our financial condition.
The accompanying unaudited condensed consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.  The accompanying unaudited condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to our ability to continue as a going concern.
Recently Adopted Accounting Pronouncements
For the year ended December 31, 2015 we adopted and applied retrospectively Financial Accounting Standards Board (FASB) Accounting Standards Update, or ASU, No. 2015-03, related to simplifying the presentation of debt issuance costs. This standard requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction to the liability. The adoption of ASU 2015-03 resulted in the reclassification of $226,000 of debt issuance costs in our March 31, 2015 Condensed Consolidated Statement of Cash Flows.
Recent Accounting Pronouncements
In February 2016, FASB issued ASU 2016-02 related to lease accounting. This standard requires lessees to recognize a right-of-use asset and a lease liability for most leases. This standard must be applied using a modified retrospective transition and is effective for all annual and interim periods beginning after December 15, 2018. Earlier adoption is permitted. We are evaluating how this new standard will impact the presentation of our financial statements and related disclosures.
In March 2016, FASB issued ASU 2016-08 related to revenue recognition. This standard is an amendment to ASU 2014-09 relating to revenue from contracts with customers. This amendment clarifies an entity’s revenue recognition for a performance obligation based on principal versus agent considerations. This standard must be applied retroactively to each prior reporting period presented or retrospectively with the cumulative effect of applying the standard recognized in the period adopted. As amended, the standard is effective for interim and annual periods beginning after December 15, 2017 and cannot be adopted before that effective date. We are currently evaluating the impact that this standard may have on our financial statements once it is adopted.
In March 2016, the FASB issued ASU 2016-09 that changes the accounting for certain aspects of share-based payments to employees. The guidance requires the recognition of the income tax effects of awards in the income statement when the awards vest or are settled, thus eliminating additional paid in capital pools. The guidance also allows for the employer to repurchase more of an employee’s shares for tax withholding purposes without triggering liability accounting and for making a policy election to account for forfeitures as they occur rather than on an estimated basis. The guidance is effective for interim and annual periods beginning after December 15, 2016 with early adoption permitted. We are currently evaluating the impact that this standard may have on our financial statements once it is adopted and the timing of adoption.
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.4.0.3
Net Loss Per Share
3 Months Ended
Mar. 31, 2016
Earnings Per Share [Abstract]  
Net Loss Per Share
Net Loss Per Share
Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common share equivalents outstanding for the period, determined using the treasury-stock method.
The basic and diluted net loss per share amounts for the three months ended March 31, 2016 and 2015 were computed based on the shares of common stock outstanding during the respective periods. Potentially dilutive securities excluded from the diluted loss per share calculation are as follows:
 
March 31,
 
2016
 
2015
Outstanding options to purchase common stock
9,302,348

 
8,365,741

Warrants and pre-funded warrants to purchase common stock

 
1,160,788

Total
9,302,348

 
9,526,529

XML 20 R8.htm IDEA: XBRL DOCUMENT v3.4.0.3
Cash, Cash Equivalents and Investments
3 Months Ended
Mar. 31, 2016
Cash and Cash Equivalents [Abstract]  
Cash, Cash Equivalents and Investments
Cash, Cash Equivalents and Investments
As of March 31, 2016 and December 31, 2015, all investments are classified as short-term and available-for-sale on the accompanying Condensed Consolidated Balance Sheets. We did not own any securities with unrealized loss positions as of March 31, 2016 or December 31, 2015. Investment income, which is included as a component of other income (expense), consists of interest earned.
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.4.0.3
Fair-Value Measurements
3 Months Ended
Mar. 31, 2016
Fair Value Disclosures [Abstract]  
Fair-Value Measurements
Fair-Value Measurements
On a recurring basis, we measure certain financial assets at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The accounting standard establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required:
Level 1—Observable inputs for identical assets or liabilities, such as quoted prices in active markets;
Level 2—Inputs other than quoted prices in active markets that are either directly or indirectly observable; and
Level 3—Unobservable inputs in which little or no market data exists, therefore they are developed using estimates and assumptions developed by us, which reflect those that a market participant would use.
Our fair value hierarchy for our financial assets and liabilities measured at fair value on a recurring basis are as follows:
 
March 31, 2016
 
Level 1
 
Level 2
 
Level 3
 
Total
 
(In thousands)
Assets:
 
 
 
 
 
 
 
Money-market funds classified as non-current restricted cash and investments
$
10,679

 
$

 
$

 
$
10,679

Money-market funds classified as short-term investments
12,266

 

 

 
12,266

Total
$
22,945

 
$

 
$

 
$
22,945

 
 
December 31, 2015
 
Level 1
 
Level 2
 
Level 3
 
Total
 
(In thousands)
Assets:
 
 
 
 
 
 
 
Money-market funds classified as non-current restricted cash and investments
$
10,679

 
$

 
$

 
$
10,679

Money-market funds classified as short-term investments
26,898

 

 

 
26,898

Total
$
37,577

 
$

 
$

 
$
37,577


Cash held in demand deposit accounts of $978,000 and $1.4 million is excluded from our fair-value hierarchy disclosure as of March 31, 2016 and December 31, 2015, respectively. There were no unrealized gains and losses associated with our short-term investments as of March 31, 2016 or December 31, 2015. The carrying amounts reported in the accompanying Condensed Consolidated Balance Sheets for receivables, accounts payable and other current monetary assets and liabilities approximate fair value because of the immediate or short-term maturity of these financial instruments.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.4.0.3
Inventory (Notes)
3 Months Ended
Mar. 31, 2016
Inventory Disclosure [Abstract]  
Inventory
Inventory

The components of inventory are as follows:

 
March 31, 2016
 
December 31, 2015
 
(In thousands)
Raw materials
$
104

 
$
93

Work-in-process
1,692

 
158

Finished goods
176

 
221

Total inventory
$
1,972

 
$
472



Work-in-process consists of manufactured vials of OMIDRIA which have not been packaged into finished goods.
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.4.0.3
Accrued Liabilities
3 Months Ended
Mar. 31, 2016
Payables and Accruals [Abstract]  
Accrued Liabilities
Accrued Liabilities
Accrued liabilities consisted of the following:
 
March 31,
2016
 
December 31,
2015
 
(In thousands)
Contract research and development
$
3,260

 
$
2,973

Consulting and professional fees
3,232

 
2,400

Employee compensation
2,544

 
2,590

Clinical trials
2,061

 
1,108

Other accruals
1,023

 
681

       Total accrued liabilities
$
12,120

 
$
9,752

XML 24 R12.htm IDEA: XBRL DOCUMENT v3.4.0.3
Notes Payable
3 Months Ended
Mar. 31, 2016
Debt Disclosure [Abstract]  
Notes Payable
Notes Payable
In December 2015, we entered into the Oxford/EWB Loan Agreement pursuant to which we borrowed $50.0 million. We can also borrow an additional $20.0 million in two tranches of $10.0 million each through June 30, 2017, contingent upon the satisfaction of certain conditions including minimum net revenues from OMIDRIA. The Oxford/EWB Loan Agreement requires interest-only payments through July 1, 2017. Beginning in August 2017, principal and interest payments are due through the January 1, 2020 maturity date.
The Oxford/EWB Loan Agreement contains covenants that require us to maintain $10.0 million in restricted cash and certain eligible term investments and limit or restrict our ability to enter into certain transactions. In addition, we are required to either meet an annual OMIDRIA net revenue minimum for 2016 of $70.0 million and quarterly OMIDRIA revenue minimums in 2017 and 2018, or maintain 50% of the then-outstanding note payable balance in restricted cash and certain eligible term investments. The Oxford/EWB Loan Agreement also includes provisions related to events of default, the occurrence of a material adverse effect (MAE) and changes of control. The occurrence of an event of default could result in the acceleration of the Oxford/EWB Loan Agreement and, under certain circumstances, could increase our interest rate by 5.0% per annum during the period of default. There was no event of default under the Oxford/EWB Loan Agreement as of March 31, 2016.
As of March 31, 2016, the remaining unamortized discount and debt issuance costs associated with the debt were $3.6 million and $414,000, respectively.
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.4.0.3
Commitments and Contingencies
3 Months Ended
Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
Commitments and Contingencies
Development Milestones and Product Royalties
We have retained control of worldwide commercial rights to OMIDRIA, to all of our product candidates and to our programs other than OMS103. We may be required, in connection with existing in-licensing or asset acquisition agreements, to make certain royalty and milestone payments and we cannot, at this time, determine when or if the related milestones will be achieved or whether the events triggering the commencement of payment obligations will occur. See Note 9 to our Consolidated Financial Statements for the year ended December 31, 2015 included within our Annual Report on Form 10-K as filed with the SEC on March 15, 2016.
Litigation
As described within Note 9 of the “Notes to Consolidated Financial Statements” included within our Annual Report on Form 10-K for the year ended December 31, 2015 filed with the SEC on March 15, 2016, we filed a patent infringement lawsuit against Par Pharmaceutical, Inc. and its subsidiary, Par Sterile Products, LLC (collectively, Par) following our receipt of a Paragraph IV Notice Letter from Par stating Par is seeking approval from the FDA to market a generic version of OMIDRIA. During 2016, we amended the lawsuit asserting an additional OMIDRIA patent, which was granted by the U.S. Patent and Trademark Office after Par filed its original Paragraph IV Notice Letter. We have filed suit against Par, thereby triggering a stay which is expected to remain in effect until January 2018 of the FDA’s final approval of Par’s ANDA. We continue to believe that the assertions in Par’s Paragraph IV Notice Letter do not have merit and we intend to prosecute vigorously our patent infringement claims against Par.
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.4.0.3
Shareholders' Equity
3 Months Ended
Mar. 31, 2016
Equity [Abstract]  
Shareholders' Equity
Shareholders’ Equity
Common Stock
At Market Issuance Sales Agreement - In January 2016, we entered into the ATM Agreement with JonesTrading pursuant to which we may direct JonesTrading to sell shares of our common stock with an aggregate offering price of up to $100.0 million directly on The Nasdaq Global Market, through a market maker other than on an exchange or in negotiated transactions. Any sales made under the ATM Agreement are based solely on our instructions and JonesTrading will receive a 1.7% commission from the gross proceeds. The ATM Agreement may be terminated by either party at any time upon 10 days' notice to the other party or by JonesTrading at any time in certain circumstances including the occurrence of a material adverse effect to Omeros.
Securities Offering - In February 2015, we sold 3.4 million shares of our common stock at a public offering price of $20.03 per share and sold pre-funded warrants to purchase up to 749,250 shares of our common stock at a public offering price of $20.02 per pre-funded warrant share. The public offering price for the pre-funded warrants was equal to the public offering price of our common stock, less the $0.01 per share exercise price of each pre-funded warrant. After deducting underwriter discounts and offering expenses of $4.9 million, we received net proceeds from the offering of $79.1 million.
Warrants
For the three months ended March 31, 2016, we received cash proceeds of approximately $7,500 upon the cash exercise of our then-outstanding pre-funded warrants, which had a weighted average exercise price of $0.01 per share, that resulted in the issuance of 749,250 shares of our common stock.
For the three months ended March 31, 2015, we received proceeds of $1.4 million upon the exercise of warrants to purchase approximately 126,000 shares of our common stock.
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.4.0.3
Stock-Based Compensation
3 Months Ended
Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-Based Compensation
Stock-Based Compensation
Stock-based compensation expense includes amortization of stock options granted to employees and non-employees and has been reported in our Condensed Consolidated Statements of Operations and Comprehensive Loss as follows:
 
 
Three Months Ended  
 March 31,
 
2016
 
2015
 
(In thousands)
Research and development
$
2,155

 
$
1,324

Selling, general and administrative
2,267

 
1,193

Total
$
4,422

 
$
2,517



In February 2016, in connection with our annual employee review process, we granted qualified employees options to purchase approximately 1.3 million shares of our common stock with an exercise price of $10.27.
The fair value of each option grant to employees and directors is estimated on the date of grant using the Black-Scholes option-pricing model. The following assumptions were applied to employee and director stock option grants during the periods ended:
 
Three Months Ended  
 March 31,
 
2016
 
2015
Estimated weighted-average fair value
$
6.62

 
$
13.49

Weighted-average assumptions
 
 
 
Expected volatility
74
%
 
70
%
Expected term, in years
5.7

 
6.0

Risk-free interest rate
1.44
%
 
1.51
%
Expected dividend yield
%
 
%


Stock option activity for all stock plans and related information is as follows:
 
 
Options
Outstanding
 
Weighted-
Average
Exercise
Price per
Share
 
Remaining
Contractual Life
(In years)
 
Aggregate
Intrinsic
Value
(In thousands)
Balance at December 31, 2015
8,310,235

 
$
7.97

 
 
 
 
   Granted
1,349,055

 
10.31

 
 
 
 
   Exercised
(329,013
)
 
4.87

 
 
 
 
   Forfeited
(27,929
)
 
14.51

 
 
 
 
Balance at March 31, 2016
9,302,348

 
$
8.40

 
6.54
 
$
65,720

Vested and expected to vest at March 31, 2016
9,012,412

 
$
8.30

 
6.46
 
$
64,505

Exercisable at March 31, 2016
6,486,712

 
$
7.09

 
5.50
 
$
53,722


At March 31, 2016, excluding non-employee stock options, the total estimated compensation expense to be recognized in connection with our unvested options is $16.6 million and 2,189,575 shares were available to grant.
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.4.0.3
Organization and Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2016
Accounting Policies [Abstract]  
Organization
Organization
We are a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Our first drug product OMIDRIA was approved by the United States (U.S.) Food and Drug Administration (FDA) for use during cataract surgery or intraocular lens replacement. We broadly launched OMIDRIA in the U.S. in April 2015.
Revenue Recognition
Product Sales, Net
We record revenue from OMIDRIA product sales when the product is delivered to our wholesalers.
Product sales are recorded net of estimated chargebacks and rebates, wholesaler distribution fees and estimated product returns. Accruals or allowances are established for these deductions when revenue is recognized, and actual amounts incurred are offset against the applicable accruals and allowances. We reflect each of these accruals or allowances as either a reduction in the related accounts receivable or as an accrued liability, depending on how the accrual or allowance is settled.
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant items subject to such estimates include revenue recognition, fair market value of investments, stock-based compensation expense and accruals for clinical trials and contingencies. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances; however, actual results could differ from these estimates.
Basis of Presentation
Liquidity and Capital Resources
As of March 31, 2016, we had $13.2 million in cash, cash equivalents and short-term investments. In addition, we have $10.0 million in restricted cash and investments that must be maintained in depository and investment accounts pursuant to the Loan and Security Agreement (the Oxford/EWB Loan Agreement) entered into in December 2015 with Oxford Finance LLC (Oxford) and East West Bank (EWB) as well as $679,000 used to secure a letter of credit for the Omeros Building lease. We expect to continue to incur losses until such time as OMIDRIA product sales, corporate partnerships and/or licensing revenues from products or programs are adequate to support our ongoing operating expenses and debt service. We are unable to predict if or when this may occur, and until it does occur, we will need to continue to raise additional funds through public or private equity securities sales, including under our At Market Issuance Sales Agreement (the ATM Agreement) with JonesTrading Institutional Services LLC (JonesTrading) (see Note 9 for further detail), through the incurrence of additional debt, through corporate partnerships, through asset sales or through the pursuit of collaborations and licensing arrangements related to certain of our products or programs. These conditions raise a substantial doubt about our ability to continue as a going concern. If we are unable to become cash-flow positive or to raise additional capital as and when needed, or upon acceptable terms, such failure would have a significant negative impact on our financial condition.
The accompanying unaudited condensed consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.  The accompanying unaudited condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to our ability to continue as a going concern.
Basis of Presentation
Our condensed consolidated financial statements include the financial position and results of operations of Omeros Corporation (Omeros) and our wholly owned subsidiaries. All inter-company transactions have been eliminated and we have determined we operate in one segment. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. The information as of March 31, 2016 and for the three months ended March 31, 2016 and 2015 includes all adjustments, which include normal recurring adjustments, necessary to present fairly our interim financial information. The Condensed Consolidated Balance Sheet at December 31, 2015 has been derived from our audited financial statements but does not include all of the information and footnotes required by GAAP.
The accompanying unaudited condensed consolidated financial statements and related notes thereto should be read in conjunction with the audited consolidated financial statements and related notes thereto that are included within our Annual Report on Form 10-K for the year ended December 31, 2015, which was filed with the U.S. Securities and Exchange Commission (SEC) on March 15, 2016.
Recent Accounting Pronouncements
Recently Adopted Accounting Pronouncements
For the year ended December 31, 2015 we adopted and applied retrospectively Financial Accounting Standards Board (FASB) Accounting Standards Update, or ASU, No. 2015-03, related to simplifying the presentation of debt issuance costs. This standard requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction to the liability. The adoption of ASU 2015-03 resulted in the reclassification of $226,000 of debt issuance costs in our March 31, 2015 Condensed Consolidated Statement of Cash Flows.
Recent Accounting Pronouncements
In February 2016, FASB issued ASU 2016-02 related to lease accounting. This standard requires lessees to recognize a right-of-use asset and a lease liability for most leases. This standard must be applied using a modified retrospective transition and is effective for all annual and interim periods beginning after December 15, 2018. Earlier adoption is permitted. We are evaluating how this new standard will impact the presentation of our financial statements and related disclosures.
In March 2016, FASB issued ASU 2016-08 related to revenue recognition. This standard is an amendment to ASU 2014-09 relating to revenue from contracts with customers. This amendment clarifies an entity’s revenue recognition for a performance obligation based on principal versus agent considerations. This standard must be applied retroactively to each prior reporting period presented or retrospectively with the cumulative effect of applying the standard recognized in the period adopted. As amended, the standard is effective for interim and annual periods beginning after December 15, 2017 and cannot be adopted before that effective date. We are currently evaluating the impact that this standard may have on our financial statements once it is adopted.
In March 2016, the FASB issued ASU 2016-09 that changes the accounting for certain aspects of share-based payments to employees. The guidance requires the recognition of the income tax effects of awards in the income statement when the awards vest or are settled, thus eliminating additional paid in capital pools. The guidance also allows for the employer to repurchase more of an employee’s shares for tax withholding purposes without triggering liability accounting and for making a policy election to account for forfeitures as they occur rather than on an estimated basis. The guidance is effective for interim and annual periods beginning after December 15, 2016 with early adoption permitted. We are currently evaluating the impact that this standard may have on our financial statements once it is adopted and the timing of adoption.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.4.0.3
Net Loss Per Share (Tables)
3 Months Ended
Mar. 31, 2016
Earnings Per Share [Abstract]  
Calculation of Historical Outstanding Dilutive Securities Not Included in Diluted Loss per Share
Potentially dilutive securities excluded from the diluted loss per share calculation are as follows:
 
March 31,
 
2016
 
2015
Outstanding options to purchase common stock
9,302,348

 
8,365,741

Warrants and pre-funded warrants to purchase common stock

 
1,160,788

Total
9,302,348

 
9,526,529

XML 30 R18.htm IDEA: XBRL DOCUMENT v3.4.0.3
Fair-Value Measurements (Tables)
3 Months Ended
Mar. 31, 2016
Fair Value Disclosures [Abstract]  
Financial Assets and Liabilities Measured at Fair Value on Recurring Basis
Our fair value hierarchy for our financial assets and liabilities measured at fair value on a recurring basis are as follows:
 
March 31, 2016
 
Level 1
 
Level 2
 
Level 3
 
Total
 
(In thousands)
Assets:
 
 
 
 
 
 
 
Money-market funds classified as non-current restricted cash and investments
$
10,679

 
$

 
$

 
$
10,679

Money-market funds classified as short-term investments
12,266

 

 

 
12,266

Total
$
22,945

 
$

 
$

 
$
22,945

 
 
December 31, 2015
 
Level 1
 
Level 2
 
Level 3
 
Total
 
(In thousands)
Assets:
 
 
 
 
 
 
 
Money-market funds classified as non-current restricted cash and investments
$
10,679

 
$

 
$

 
$
10,679

Money-market funds classified as short-term investments
26,898

 

 

 
26,898

Total
$
37,577

 
$

 
$

 
$
37,577

XML 31 R19.htm IDEA: XBRL DOCUMENT v3.4.0.3
Inventory (Tables)
3 Months Ended
Mar. 31, 2016
Inventory Disclosure [Abstract]  
Schedule of Inventory, Current
he components of inventory are as follows:

 
March 31, 2016
 
December 31, 2015
 
(In thousands)
Raw materials
$
104

 
$
93

Work-in-process
1,692

 
158

Finished goods
176

 
221

Total inventory
$
1,972

 
$
472

XML 32 R20.htm IDEA: XBRL DOCUMENT v3.4.0.3
Accrued Liabilities (Tables)
3 Months Ended
Mar. 31, 2016
Payables and Accruals [Abstract]  
Accrued Liabilities
Accrued liabilities consisted of the following:
 
March 31,
2016
 
December 31,
2015
 
(In thousands)
Contract research and development
$
3,260

 
$
2,973

Consulting and professional fees
3,232

 
2,400

Employee compensation
2,544

 
2,590

Clinical trials
2,061

 
1,108

Other accruals
1,023

 
681

       Total accrued liabilities
$
12,120

 
$
9,752

XML 33 R21.htm IDEA: XBRL DOCUMENT v3.4.0.3
Stock-Based Compensation (Tables)
3 Months Ended
Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-Based Compensation Expense
Stock-based compensation expense includes amortization of stock options granted to employees and non-employees and has been reported in our Condensed Consolidated Statements of Operations and Comprehensive Loss as follows:
 
 
Three Months Ended  
 March 31,
 
2016
 
2015
 
(In thousands)
Research and development
$
2,155

 
$
1,324

Selling, general and administrative
2,267

 
1,193

Total
$
4,422

 
$
2,517

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions
The following assumptions were applied to employee and director stock option grants during the periods ended:
 
Three Months Ended  
 March 31,
 
2016
 
2015
Estimated weighted-average fair value
$
6.62

 
$
13.49

Weighted-average assumptions
 
 
 
Expected volatility
74
%
 
70
%
Expected term, in years
5.7

 
6.0

Risk-free interest rate
1.44
%
 
1.51
%
Expected dividend yield
%
 
%
Stock Option Activity and Related Information
Stock option activity for all stock plans and related information is as follows:
 
 
Options
Outstanding
 
Weighted-
Average
Exercise
Price per
Share
 
Remaining
Contractual Life
(In years)
 
Aggregate
Intrinsic
Value
(In thousands)
Balance at December 31, 2015
8,310,235

 
$
7.97

 
 
 
 
   Granted
1,349,055

 
10.31

 
 
 
 
   Exercised
(329,013
)
 
4.87

 
 
 
 
   Forfeited
(27,929
)
 
14.51

 
 
 
 
Balance at March 31, 2016
9,302,348

 
$
8.40

 
6.54
 
$
65,720

Vested and expected to vest at March 31, 2016
9,012,412

 
$
8.30

 
6.46
 
$
64,505

Exercisable at March 31, 2016
6,486,712

 
$
7.09

 
5.50
 
$
53,722

XML 34 R22.htm IDEA: XBRL DOCUMENT v3.4.0.3
Organization and Significant Accounting Policies (Detail)
$ in Thousands
3 Months Ended
Mar. 31, 2016
USD ($)
segment
Mar. 31, 2015
USD ($)
Increase (decrease) in prepaid expenses and other noncurrent assets $ 420 $ (725)
Increase (decrease) in accounts payable and accrued expenses $ 1,272 (2,170)
Number of operating segments | segment 1  
Cash, cash equivalents and short-term investments $ 13,200  
Accounting Standards Update 2015-03    
Increase (decrease) in prepaid expenses and other noncurrent assets   (226)
Increase (decrease) in accounts payable and accrued expenses   $ 226
Cash and Eligible Investments    
Restricted cash and investments 10,000  
Cash    
Restricted cash and investments $ 679  
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.4.0.3
Net Loss Per Share - Calculation of Historical Outstanding Dilutive Securities Not Included in Diluted Loss Per Share (Detail) - shares
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Outstanding dilutive securities not included in diluted loss per share calculation 9,302,348 9,526,529
Outstanding options to purchase common stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Outstanding dilutive securities not included in diluted loss per share calculation 9,302,348 8,365,741
Warrants and pre-funded warrants to purchase common stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Outstanding dilutive securities not included in diluted loss per share calculation 0 1,160,788
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.4.0.3
Fair-Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Measurements, Recurring - USD ($)
$ in Thousands
Mar. 31, 2016
Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Total $ 22,945 $ 37,577
Restricted Cash, Noncurrent    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Money-market funds, fair value disclosure 10,679 10,679
Short-term Investments    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Money-market funds, fair value disclosure 12,266 26,898
Fair Value, Inputs, Level 1    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Total 22,945 37,577
Fair Value, Inputs, Level 1 | Restricted Cash, Noncurrent    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Money-market funds, fair value disclosure 10,679 10,679
Fair Value, Inputs, Level 1 | Short-term Investments    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Money-market funds, fair value disclosure 12,266 26,898
Fair Value, Inputs, Level 2    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Total 0 0
Fair Value, Inputs, Level 2 | Restricted Cash, Noncurrent    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Money-market funds, fair value disclosure 0 0
Fair Value, Inputs, Level 2 | Short-term Investments    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Money-market funds, fair value disclosure 0 0
Fair Value, Inputs, Level 3    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Total 0 0
Fair Value, Inputs, Level 3 | Restricted Cash, Noncurrent    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Money-market funds, fair value disclosure 0 0
Fair Value, Inputs, Level 3 | Short-term Investments    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Money-market funds, fair value disclosure $ 0 $ 0
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.4.0.3
Fair-Value Measurements - Narrative (Detail) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2016
Dec. 31, 2015
Fair Value Disclosures [Abstract]    
Cash excluded from fair value hierarchy disclosure $ 978,000 $ 1,400,000
Unrealized gain (loss) on investments $ 0 $ 0
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.4.0.3
Inventory (Details) - USD ($)
$ in Thousands
Mar. 31, 2016
Dec. 31, 2015
Inventory Disclosure [Abstract]    
Raw materials $ 104 $ 93
Work-in-process 1,692 158
Finished goods 176 221
Inventory $ 1,972 $ 472
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.4.0.3
Accrued Liabilities - Accrued Liabilities (Detail) - USD ($)
$ in Thousands
Mar. 31, 2016
Dec. 31, 2015
Payables and Accruals [Abstract]    
Contract research and development $ 3,260 $ 2,973
Consulting and professional fees 3,232 2,400
Employee compensation 2,544 2,590
Clinical trials 2,061 1,108
Other accruals 1,023 681
Total accrued liabilities $ 12,120 $ 9,752
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.4.0.3
Notes Payable (Detail) - Oxford EWB Loan
12 Months Ended
Dec. 31, 2015
USD ($)
Mar. 31, 2016
USD ($)
tranche
Debt Instrument [Line Items]    
Loan and security agreement, existing outstanding indebtedness $ 50,000,000  
Line of credit, accordion feature, limit increase   $ 20,000,000
Line of credit, accordion feature, number of tranches | tranche   2
Line of credit, accordion feature, increase per tranche   $ 10,000,000
Debt instrument, covenant compliance, restricted cash and certain eligible term investments 10,000,000  
Debt instrument, covenant compliance, minimum annual net revenue requirements $ 70,000,000  
Debt instrument, covenant compliance, minimum restricted cash and eligible term investments as a percent of outstanding balance 50.00%  
Potential additional default interest 5.00%  
Unamortized balance of debt discount   3,600,000
Unamortized balance of debt issuance costs   $ 414,000
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.4.0.3
Shareholders' Equity (Detail) - USD ($)
1 Months Ended 3 Months Ended
Feb. 28, 2015
Mar. 31, 2016
Mar. 31, 2015
Jan. 31, 2016
Class of Stock [Line Items]        
Stock issued during period 3,400,000      
Share price (in USD per share) $ 20.03      
Shares of common stock to purchase by warrant 749,250      
Exercise price of warrants (in USD per share) $ 0.01      
Offering expenses and underwriter discounts $ 4,900,000      
Proceeds from issuance of common stock and pre-funded warrants, net $ 79,100,000 $ 0 $ 79,076,000  
Proceeds from warrant exercises   $ 7,500 $ 1,400,000  
Stock Issued During Period, Shares, Other   749,250    
Warrants exercised during period     126,000  
Pre-funded Warrants        
Class of Stock [Line Items]        
Share price (in USD per share) $ 20.02      
At The Market (ATM) Program [Member]        
Class of Stock [Line Items]        
Common Stock Value Authorized under Stock Offering Program       $ 100,000,000
Stock Offering Program, Commission Percent   1.70%    
Stock Offering Program, Notice Period for Termination   10 days    
Weighted Average        
Class of Stock [Line Items]        
Exercise price of warrants (in USD per share)   $ 0.01    
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.4.0.3
Stock-Based Compensation - Narrative (Detail) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended 3 Months Ended
Feb. 29, 2016
Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Granted (shares)   1,349,055
Granted (USD per share)   $ 10.31
Unrecognized compensation expense   $ 16.6
Equity Incentive Plan 2008    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Shares available for future grants   2,189,575
Stock options    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Granted (shares) 1,269,055  
Granted (USD per share) $ 10.27  
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.4.0.3
Stock-Based Compensation - Stock-Based Compensation Expense (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Total $ 4,422 $ 2,517
Research and Development Expense    
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Stock-based compensation expense 2,155 1,324
Selling, General and Administrative Expenses    
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Stock-based compensation expense $ 2,267 $ 1,193
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.4.0.3
Stock-Based Compensation - Fair Value of Employee Option Grant Estimated on Date of Grant (Details) - Equity Option - $ / shares
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Estimated weighted-average fair value (USD per share) $ 6.62 $ 13.49
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]    
Expected volatility 74.00% 70.00%
Weighted Average    
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]    
Expected term, in years 5 years 8 months 26 days 6 years 18 days
Risk-free interest rate 1.44% 1.51%
Expected dividend yield 0.00% 0.00%
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.4.0.3
Stock-Based Compensation - Summary of Stock Option Activity and Related Information (Detail)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2016
USD ($)
$ / shares
shares
Options Outstanding  
Beginning balance (shares) | shares 8,310,235
Granted (shares) | shares 1,349,055
Exercised (shares) | shares (329,013)
Forfeited (shares) | shares (27,929)
Ending balance (shares) | shares 9,302,348
Vested and expected to vest (shares) | shares 9,012,412
Exercisable (shares) | shares 6,486,712
Weighted-Average Exercise Price per Share  
Beginning balance (USD per share) | $ / shares $ 7.97
Granted (USD per share) | $ / shares 10.31
Exercised (USD per share) | $ / shares 4.87
Forfeited (USD per share) | $ / shares 14.51
Ending balance (USD per share) | $ / shares 8.40
Vested and expected to vest (USD per share) | $ / shares 8.30
Exercisable (USD per share) | $ / shares $ 7.09
Weighted- Average Remaining Contractual Life  
Balance (in years) 6 years 5 months 45 days
Vested and expected to vest (in years) 6 years 5 months 15 days
Exercisable (in years) 5 years 5 months 30 days
Aggregate Intrinsic Value  
Balance | $ $ 65,720
Vested and expected to vest | $ 64,505
Exercisable | $ $ 53,722
EXCEL 46 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 50 FilingSummary.xml IDEA: XBRL DOCUMENT 3.4.0.3 html 58 157 1 false 20 0 false 6 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.omeros.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.omeros.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.omeros.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Sheet http://www.omeros.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Statements 4 false false R5.htm 1003000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.omeros.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 5 false false R6.htm 2101100 - Disclosure - Organization and Significant Accounting Policies Sheet http://www.omeros.com/role/OrganizationAndSignificantAccountingPolicies Organization and Significant Accounting Policies Notes 6 false false R7.htm 2102100 - Disclosure - Net Loss Per Share Sheet http://www.omeros.com/role/NetLossPerShare Net Loss Per Share Notes 7 false false R8.htm 2104100 - Disclosure - Cash, Cash Equivalents and Investments Sheet http://www.omeros.com/role/CashCashEquivalentsAndInvestments Cash, Cash Equivalents and Investments Notes 8 false false R9.htm 2106100 - Disclosure - Fair-Value Measurements Sheet http://www.omeros.com/role/FairValueMeasurements Fair-Value Measurements Notes 9 false false R10.htm 2108100 - Disclosure - Inventory (Notes) Notes http://www.omeros.com/role/InventoryNotes Inventory (Notes) Notes 10 false false R11.htm 2110100 - Disclosure - Accrued Liabilities Sheet http://www.omeros.com/role/AccruedLiabilities Accrued Liabilities Notes 11 false false R12.htm 2112100 - Disclosure - Notes Payable Notes http://www.omeros.com/role/NotesPayable Notes Payable Notes 12 false false R13.htm 2113100 - Disclosure - Commitments and Contingencies Sheet http://www.omeros.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 13 false false R14.htm 2115100 - Disclosure - Shareholders' Equity Sheet http://www.omeros.com/role/ShareholdersEquity Shareholders' Equity Notes 14 false false R15.htm 2116100 - Disclosure - Stock-Based Compensation Sheet http://www.omeros.com/role/StockBasedCompensation Stock-Based Compensation Notes 15 false false R16.htm 2201201 - Disclosure - Organization and Significant Accounting Policies (Policies) Sheet http://www.omeros.com/role/OrganizationAndSignificantAccountingPoliciesPolicies Organization and Significant Accounting Policies (Policies) Policies http://www.omeros.com/role/OrganizationAndSignificantAccountingPolicies 16 false false R17.htm 2302301 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.omeros.com/role/NetLossPerShareTables Net Loss Per Share (Tables) Tables http://www.omeros.com/role/NetLossPerShare 17 false false R18.htm 2306301 - Disclosure - Fair-Value Measurements (Tables) Sheet http://www.omeros.com/role/FairValueMeasurementsTables Fair-Value Measurements (Tables) Tables http://www.omeros.com/role/FairValueMeasurements 18 false false R19.htm 2308301 - Disclosure - Inventory (Tables) Sheet http://www.omeros.com/role/InventoryTables Inventory (Tables) Tables http://www.omeros.com/role/InventoryNotes 19 false false R20.htm 2310301 - Disclosure - Accrued Liabilities (Tables) Sheet http://www.omeros.com/role/AccruedLiabilitiesTables Accrued Liabilities (Tables) Tables http://www.omeros.com/role/AccruedLiabilities 20 false false R21.htm 2316301 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.omeros.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.omeros.com/role/StockBasedCompensation 21 false false R22.htm 2401402 - Disclosure - Organization and Significant Accounting Policies (Detail) Sheet http://www.omeros.com/role/OrganizationAndSignificantAccountingPoliciesDetail Organization and Significant Accounting Policies (Detail) Details http://www.omeros.com/role/OrganizationAndSignificantAccountingPoliciesPolicies 22 false false R23.htm 2402402 - Disclosure - Net Loss Per Share - Calculation of Historical Outstanding Dilutive Securities Not Included in Diluted Loss Per Share (Detail) Sheet http://www.omeros.com/role/NetLossPerShareCalculationOfHistoricalOutstandingDilutiveSecuritiesNotIncludedInDilutedLossPerShareDetail Net Loss Per Share - Calculation of Historical Outstanding Dilutive Securities Not Included in Diluted Loss Per Share (Detail) Details 23 false false R24.htm 2406402 - Disclosure - Fair-Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) Sheet http://www.omeros.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail Fair-Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) Details 24 false false R25.htm 2406403 - Disclosure - Fair-Value Measurements - Narrative (Detail) Sheet http://www.omeros.com/role/FairValueMeasurementsNarrativeDetail Fair-Value Measurements - Narrative (Detail) Details 25 false false R26.htm 2408402 - Disclosure - Inventory (Details) Sheet http://www.omeros.com/role/InventoryDetails Inventory (Details) Details http://www.omeros.com/role/InventoryTables 26 false false R27.htm 2410402 - Disclosure - Accrued Liabilities - Accrued Liabilities (Detail) Sheet http://www.omeros.com/role/AccruedLiabilitiesAccruedLiabilitiesDetail Accrued Liabilities - Accrued Liabilities (Detail) Details 27 false false R28.htm 2412401 - Disclosure - Notes Payable (Detail) Notes http://www.omeros.com/role/NotesPayableDetail Notes Payable (Detail) Details http://www.omeros.com/role/NotesPayable 28 false false R29.htm 2415402 - Disclosure - Shareholders' Equity (Detail) Sheet http://www.omeros.com/role/ShareholdersEquityDetail Shareholders' Equity (Detail) Details http://www.omeros.com/role/ShareholdersEquity 29 false false R30.htm 2416402 - Disclosure - Stock-Based Compensation - Narrative (Detail) Sheet http://www.omeros.com/role/StockBasedCompensationNarrativeDetail Stock-Based Compensation - Narrative (Detail) Details 30 false false R31.htm 2416403 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail) Sheet http://www.omeros.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail Stock-Based Compensation - Stock-Based Compensation Expense (Detail) Details 31 false false R32.htm 2416404 - Disclosure - Stock-Based Compensation - Fair Value of Employee Option Grant Estimated on Date of Grant (Details) Sheet http://www.omeros.com/role/StockBasedCompensationFairValueOfEmployeeOptionGrantEstimatedOnDateOfGrantDetails Stock-Based Compensation - Fair Value of Employee Option Grant Estimated on Date of Grant (Details) Details 32 false false R33.htm 2416405 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity and Related Information (Detail) Sheet http://www.omeros.com/role/StockBasedCompensationSummaryOfStockOptionActivityAndRelatedInformationDetail Stock-Based Compensation - Summary of Stock Option Activity and Related Information (Detail) Details 33 false false All Reports Book All Reports omer-20160331.xml omer-20160331.xsd omer-20160331_cal.xml omer-20160331_def.xml omer-20160331_lab.xml omer-20160331_pre.xml true true ZIP 52 0001285819-16-000017-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001285819-16-000017-xbrl.zip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end